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ABSTRACT

Generation of foam cells, an essential step for reverse cholesterol transport (RCT)
studies, uses the technique of receptor dependent macrophage loading with radiolabeled
acetylated Low Density Lipoprotein (Ac-LDL). In this study, we used the ability of a
biologically relevant detergent molecule, Lysophosphatidylcholine (Lyso PtdCho), to form
mixed micelles with cholesterol or cholesteryl ester (CE) to generate macrophage foam
cells. Fluorescent or radiolabelled cholesterol / Lyso PtdCho mixed micelles were
prepared and incubated with RAW 264.7 or mouse peritoneal macrophages. Results
showed that such micelles were quite stable at 4°C and retained the solubilized
cholesterol during one month storage. Macrophages incubated with cholesterol or CE
(unlabeled, fluorescently labeled or radiolabeled) / Lyso PtdCho mixed micelles
accumulated CE as documented by microscopy, lipid staining, labeled oleate
incorporation, and by thin layer chromatography (TLC). Such foam cells unloaded
cholesterol when incubated with high density lipoprotein (HDL) and not with oxidized HDL
(Ox-HDL). We propose that stable cholesterol or CE / Lyso PtdCho micelles would offer
advantages over existing methods.
Oxidative stress is associated with heart failure (HF). Previously our research
group observed that the patients with low left-ventricular ejection fraction showed
accumulation of high level of oxidized LDL (Ox-LDL) when compared with the heart failure
patients with normal range of ejection fraction (EF). HDL is known to be atheroprotective
and one of its important antioxidative functions is to protect LDL from oxidative
modifications. However, HDL itself undergoes oxidation and Ox-HDL becomes
functionally poor. It is expected to have a diminished ability to promote reverse cholesterol
3

transport. Therefore, it was hypothesized that the quality of HDL present in the patients
with EF would more compromised than those present in the patients with normal EF.
Functionality of HDL was evaluated by measuring its cholesterol efflux capacity from foam
cells generated in vitro. Functionality of HDL, which is strongly related to the oxidative
modifications of HDL was further estimated by measuring paraoxonase 1 (PON1) enzyme
activity associated with HDL. Higher the PON1 activity and RCT ability, better is the
functionality of HDL.
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CHAPTER 1: GENERAL INTRODUCTION
Coronary Artery Diseases
Coronary artery diseases (CAD) are the most common pathobiological
conditions associated with atherosclerosis (1). CAD is the main cause of death in
Western societies (2). In United States alone one third of all deaths above the age
of 35 are caused by CAD. Out of 15 million CAD cases in United States
approximately 8 million people are known to suffer heart attacks and around half
a million people die from it every year. Moreover, millions of people suffer from
severe atherosclerosis without showing any symptoms. The cost to manage CAD
which includes health care services and loss of productivity of the sufferers could
build up to more than $100 billion per year (3, 4).

Atherosclerosis
The term atherosclerosis (synonymously used with arteriosclerosis) was
first introduced in 1829 by Jean Lobstein (1). Atherosclerosis is often studied as a
type of chronic systemic inflammation and is characterized by progressive lesion
formation and narrowing of arteries. The risk factors associated with
atherosclerosis are often heritable, known as ‘run in the family’ (5). However, in
the modern industrialized society atherosclerosis and CAD are more often initiated
by environmental factors, such as, smoking, obesity, diabetes and lack of physical
activity. Atherosclerosis is a dynamic process and initiates with the formation of
fatty streaks on the innermost layer of arterial wall, known as tunica intima. Fatty
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streaks contain mainly lipid loaded macrophages known as foam cells and other
immune cells such as T-cells, dendritic cells and mast cells (6). Autopsies of young
individuals revealed the presence of fatty streaks on the arterial walls which are
generally asymptomatic (7). These fatty streaks can develop into atheromas over
the time or can regress with the change in life style, diet and exercise (8).
Atheroma or atherosclerotic plaques are complex in structure and contain
lipid laden foam cells, extracellular lipid droplets, mainly cholesterol crystals,
apoptotic cells and cellular debris in the necrotic core. Plaques are covered by
smooth muscle cells and collagen-rich matrix to form a fibrous cap (Figure 1) (6).
Advanced lesions are frequently associated with calcium deposition. Calcification
of lesions is positively correlated with plaque burden and believed to have a
protective action against plaque rupture which is often fatal (9).
Growing plaques can prevent regular blood flow in the coronary artery by
progressively narrowing the arterial lumen and cause flow-limiting stenosis and
ischemic conditions. However, the most severe clinical implications are generally
associated with atherosclerotic plaque rupture. When the fibrous cap is weak or
damaged, the plaque becomes vulnerable by the action of activated immune cells
and inflammatory cytokine. Disruption of plaque leads to exposure of thrombogenic
material located in the core of the plaque, to arterial circulation, resulting in platelet
aggregation and the formation of thrombus, which eventually can lead to
myocardial infarction, heart failure and ischemic stroke (Fig. 1) (10).
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Figure 1. Atherosclerotic Plaque Development and Rupture.
Injury to the tunica intima of endothelial layer of arterial lining initiates plaque formation.
Accumulation of modified LDL set off a chain reaction that leads to generation of fatty streaks. Fatty
streaks contain large amount of free and esterified cholesterol, inflammatory immune cells, necrotic
cells and foam cells. Calcification can stabilize the atheroma, while rupture of plaque leads to
thrombosis which can result in acute myocardial infraction, stroke and heart attack.
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Low Density Lipoproteins
Low density lipoproteins (LDLs), the large spherical particles containing
cholesteryl ester (CE) core, are the major carrier of cholesterol in plasma. Besides
being the largest pool of CE in the human plasma LDL also contains small amount
of triglycerides in the neutral lipid core. The highly hydrophobic lipid core is
surrounded by amphiphilic phospholipids and apolipoprotein B-100 (apo B-100).
LDLs are derived from triglyceride-rich very-low-density lipoproteins (VLDLs) by
the action of hepatic lipase. Normally LDL remains in the blood circulation for 2-3
days (11). About 75% of the LDL particles are absorbed by liver via LDL receptor
for which apolipoprotein B-100 on the LDL serves as the ligand. Binding of LDL to
the receptor initiates endocytosis of the particle and fusion of LDL containing
vesicle to lysosomes, followed by LDL receptor recycling. Lysosomal degradation
of LDL generates fatty acids, cholesterol, glycerol and amino acids as the primary
components of LDL. Free cholesterol incorporated in the cytoplasmic cholesterol
pool is utilized for membrane and steroid synthesis and remaining cholesterol gets
esterified into highly hydrophobic CE (12).

Oxidized LDL
Atherosclerosis is closely associated with the lipid accumulation in the
tunica intima of the artery. Lipid-laden foam cells, which are found in the
atherosclerotic plaque, are known to derive its cholesterol burden from LDL (13).
However, macrophages express limited number of LDL receptors and the
accumulation of cholesterol in macrophages do not add up to the amount of
4

cholesterol stored via LDL receptor mediated uptake (14), which is also regulated
by a feedback mechanism (15). LDL are considered to be risk factors for CAD
because oxidative modification of LDL makes them highly atherogenic. Increased
plasma level of LDL make them prone to a number of modifications by several
ways which in turn induce a series of events leading to fatty streak formation.
Increased plasma level of LDL not only increases intimal LDL level, but also
causes enhanced adherence of circulating monocytes to the arterial endothelial
cell lining. Cells found in the atherosclerotic plaque, such as endothelial cells,
smooth muscle cells, fibroblasts, neutrophils, monocytes and macrophages can
catalyze the oxidation of LDL. Pro-atherogenic events induced by modified LDL
are complex. Oxidized LDL (Ox-LDL) recruits monocytes to adhere and penetrate
the arterial intima by stimulating monocyte chemotactic factor (MCP-1) from the
endothelial cells. Adherence of monocytes to endothelial cells is associated with
Ox-LDL stimulated endothelial secretion of intercellular adhesion molecule 1
(ICAM-1) and vascular adhesion molecule 1 (VCAM-1). Ox-LDL can induce the
release of macrophage colony stimulating factor (MCSF) which prompts
differentiation of monocytes into adherent macrophages. Ox-LDL itself can act as
a chemotactic factor to attract patrolling monocytes. ‘Trapping’ of macrophages in
the intimal region initiates the fatty streak formation as the scavenger receptors
(SR) present on the macrophages play a crucial role in cholesterol accumulation.
Ox-LDL is also believed to cause injury in the endothelial lining of the intima (Fig.
2) (14, 16).
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The characteristic feature of modified LDL is the gain of a net negative
charge which makes them unrecognizable by classical LDL receptors, but converts
them into ligands for SR present on macrophages. Oxidation of lipid component
can generate peroxidized lipids which in turn can give rise to aldehydes and leads
to the alteration of the structure of the protein moiety. Apolipoproteins themselves
can undergo oxidative modification resulting in cross-linking, proteolysis, structural
modification and alteration in amino acid compositions of the protein moiety. In
vitro studies of the oxidative modifications of LDL revealed metal ion such as
copper, enzyme such as lipoxygenase (Fig. 2), oxygen radicals, reactive nitrogen
species generated by hydrogen peroxide or myeloperoxidases (17), peroxides and
superoxides play vital role in the oxidation of LDL and make Ox-LDL recognizable
by SR (Fig. 2) (18, 19).

Macrophages and Scavenger Receptors
Macrophages are commonly associated with innate immune system and
phagocytosis. In case of atherosclerosis, macrophages play a very critical role in
the development of plaque mostly due to its unique features associated with
immune surveillance. During the initiation stage of fatty streak formation, once
monocytes are recruited and differentiated into macrophages in the intimal region,
macrophages express a number of SR. SR are cell-membrane proteins and bind
to a wide variety of ligands including chemically or biologically modified lipoproteins
(20). In 1979 Goldstein et al. discovered that macrophages utilize their scavenging
mechanism to uptake modified LDL from plasma. It was also discovered that the
6

macrophage mediated endocytosis of modified LDL takes place via a different
receptor than the classical LDL receptor (21, 22). Expression of SR are closely
associated with adherence of cells as fully differentiated macrophages only and
not the freshly isolated monocytes express high level of SR (23).

Scavenger Receptor Class A:
There are two major classes of SR: scavenger receptor class A (SR-A) and
scavenger receptor class B (SR-B). SR-AI/II (type I and II) are generally present
on the cell-surface of tissue macrophages such as Kupffer cells and can be
induced in other cell types (24). Two types of SR-A are derived by alternative
mRNA splicing and SR-AI is different from SR-AII by having a cysteine–linked Cterminal extension. SR-A are expressed as transmembrane glycoproteins and the
collagen like domain form a positively charged groove due to the presence of lysine
and is involved in the binding of negatively charged ligands (25). They play an
important role in the phagocytosis of apoptotic cells, in cell adhesion, antigen
recognition and processing (20). SR-A bind to several polyanionic macromolecules
such as bacterial surface components- lipopolysaccharides and lipoteichoic acid,
polyribonucleotides (polyguanosinic acid and polyinosinic acid), dextran sulfate
and anionic phospholipids such as phosphatidylserine (25). SR-A are also known
as pattern recognition receptors as they bind to microbial surface proteins of the
same molecular pattern expressed by a wide range of bacteria (26). SR-A
expression are regulated by cytokines and atherosclerotic lesions are known to
have abundant expression of SR-A (25). Initially SR-A were thought to be
7

associated with the binding of acetylated LDL (Ac-LDL). However, as Ac-LDL is
absent in vivo, the role of SR-A in the endocytosis of Ox-LDL was studied more
thoroughly (24). It has been suggested that while SR-A are responsible for the
uptake of 80% and 50% of Ac-LDL and Ox-LDL respectively. Even though its
efficiency to uptake Ox-LDL is much lesser than that of Ac-LDL, SR-A knockout
mice showed significant reduction in atherosclerotic lesions in otherwise
atherosclerotic mice model (20).

Scavenger Receptor Class B:
CD36, a member of SR-B family is associated with Ox-LDL uptake. CD36
along with SR-A are known to be responsible for 75-90% of the uptake and
degradation of Ac-LDL and Ox-LDL (27). CD36 is an 88-KDa membrane
glycoprotein and unlike SR-A, it is more ubiquitous in expression. CD36 is
expressed by adipocytes, skeletal muscle cells, microvascular endothelial and
smooth muscle cells along with a number of hematocytes such as platelets,
dendritic cells, monocytes and macrophages (20, 24). Previous studies have
shown that CD36 can bind to minimally modified LDL (mm-LDL), a form that is
capable of initiating monocyte migration and “trapping”. In CD36 knockout mice,
Ox-LDL binding and endocytosis by peritoneal macrophages is known to be
decreased by 60-80% and the atherosclerotic lesion burden is reduced by 70%
when CD36- apoE double knockout mice are fed a high-fat diet (20). In human
subjects lacking CD36, monocyte derived macrophages showed 40% reduction in
Ox-LDL endocytosis (24). Besides Ox-LDL, the other biologically relevant ligands
8

for CD36 are apoptotic cells, cell debris, Plasmodium falciparum parasitized
erythrocytes, sickle cell erythrocytes, collagens type I and IV, anionic
phospholipids and long-chain fatty acids. However, unlike SR-A, CD36 does not
bind to a host of polyanionic ligands such as fucoidan, polyribonucleic acids and
carrageenan (20, 24).

Cholesterol Accumulation and Foam Cells
Even though the majority of the cholesterol accumulation mediated by
modified LDL takes place via SR, a number of studies documented different
sources and pathways of cholesterol accumulation. Blocking of SR-A and SR-B
together prevented the modified LDL uptake by 75-90%, but could not inhibit the
cholesterol accumulation completely (28). This observation directed the study to
understand the unique and not-so-common pathways of foam cell development.
Kruth et al (29, 30) reported the mechanism for receptor-independent uptake of
native LDL by macrophages and subsequent development of foam cells.
According to this model monocyte-derived macrophages upon activation take up
native and modified LDL by fluid-phase endocytosis, otherwise known as
macropinocytosis.

In

this

actin-dependent

endocytic

pathway

activated

macrophages enclose the surrounding fluid within a vacuole by plasma membrane
fusion and engulf the vacuole to internalize the surrounding fluid. This observation
was highly valuable as it explains why infectious agents, and inflammatory
cytokines released from the atherosclerotic plaque induce LDL uptake in its various
forms (29, 30). Furthermore, macrophages can internalize aggregated LDL, which
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are too large to fit in the pinocytic vesicles, by phagocytosis (31). Yet another
model of foam cell development suggests that the presence of sphingomyelinase,
an enzyme found in arterial wall and in the atherosclerotic lesions, promotes LDL
receptor mediated native LDL and SR mediated Ac-LDL uptake (32).
The fundamental mechanisms associated with the foam cell development
are acyl-CoA: cholesterol O-acyltransferase (ACAT) activation and

CE

accumulation (Fig. 3). Excess of free cholesterol in cells can be highly cytotoxic
and generally it is converted into CE for storage. Accumulation of cholesterol by
foam cells is a two-step process: i) lysosome mediated hydrolysis of CE present in
modified LDL to produce free cholesterol, ii) re-esterification of free cholesterol in
presence of ACAT to CE as the lipid droplets in the cytoplasm (33). However, the
studies by Tangirala et al (34, 35) suggested that in the advanced stage of
atherosclerotic lesion formation lysosome itself can serve as the pool of free
cholesterol and CE crystals. In older plaques macrophages and smooth muscle
cells exhibited such cytoplasmic and lysosomal lipid droplet accumulation and
appeared to be independent of ACAT activation (34, 35). Cholesterol accumulation
and retention in both free and esterified form initiate the process of fatty streak
formation.
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Figure 2. Role of Modified LDL in the Initiation of Fatty Streak Formation.
Increased plasma concentration of LDL leads to accumulation of LDL in the subendothelial space
and oxidative modification by 15 lipoxygenase. Ox-LDL acts as a chemoattractant and recruits
monocytes to differentiate into tissue macrophages. Monocyte adherence to the endothelial layer
is facilitated by VCAM and ICAM; migration of monocytes to the subendothelial space is achieved
with the help of MCP-1, Differentiation of monocytes to macrophages is associated with M-CSF.
Macrophages express scavenger receptors and facilitate the uptake of modified LDL. Cholesterol
present in the LDL is quickly esterified into CE by the enzyme ACAT and stored as lipid droplets.
Lipid enriched macrophages or foam cells are the core structure of fatty streaks and eventual
atherosclerotic plaques.
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Figure 3. Esterification of Free Cholesterol for storage.
Free cholesterol which is highly cytotoxic gets converted into highly hydrophobic CE with the help
of the enzyme ACAT. CE crystals are stored in the cytoplasm and lysosomes of the cells.
Macrophages are highly efficient in esterification and storage of cholesterol. This reaction is
reversible and CE is hydrolyzed to produce cholesterol which gets utilized for cell membrane repair
or generation and hormone synthesis.
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In Vitro Generation of Foam Cells with Cholesterol Analogue
Foam cells generated in vitro have been a very important tool to study
atherosclerotic plaque formation as well as regression. As mentioned earlier,
generally modified LDL (Ac-LDL and Ox-LDL) are used to generate foam cells.
Isolated LDL undergoes acetylation or oxidation in presence of acetic anhydride or
copper ion respectively. To follow the distribution and the fate of the incorporated
cholesterol, radiolabeled cholesterol (3H or 14C-cholesterol) is often used. In recent
years fluorescently labeled cholesterol has been used for various studies such as
to investigate the distribution of cholesterol in cell membrane (36), to understand
the effects of sterol carrier protein and apolipoprotein E (apoE) on high density
lipoprotein (HDL) mediated cholesterol efflux (37) and HDL recycling (38), to
develop high-throughput cholesterol efflux assays (39) and to explore the
mechanism of cholesterol absorption and storage in the in vivo animal model (40).
NBD- cholesterol is a commercially available, frequently used fluorescently
labeled cholesterol analog. NBD group present in the 22-NBD-cholesterol or 22(N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino)-23, 24-bisnor-5-cholen-3b-ol, is
responsible for the fluorescent nature and the excitation wavelength for NBD is
485 nm. The emission spectra range for NBD varies between 535- 545 nm
depending on ethanol or aqueous solution respectively (Fig. 4) (41).
Macrophages, hepatocytes, fibroblasts and lymphocytes have been loaded
with NBD-cholesterol. Previous studies suggest that NBD-cholesterol can be very
effectively used to study the cellular uptake and trafficking of the cholesterol.
However, use of NBD-cholesterol to investigate the distribution of cholesterol in
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the plasma membrane produced ambiguous results (41). NBD-cholesterol is
potentially a reliable, easy-to-use cholesterol analogue and can be substituted for
radiolabeled cholesterol.
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Figure 4. Fluorescent analogue of Cholesterol.
22-NBD-cholesterol has 22-(N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino)-23, 24-bisnor-5-cholen3b-ol, group attached to cholesterol. It is visualized as green fluorescent probe. The excitation
wavelength for NBD is 485 nm and the emission spectra range for NBD varies between 535- 545
nm.
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Reverse Cholesterol Transport
In 1968 Glomset (42) proposed the existence of a mechanism which is
involved in the transport of cholesterol from peripheral tissues to the liver and is
believed to maintain the cholesterol homeostasis (42). Studies from the last four
decades have established that Reverse Cholesterol Transport (RCT) is one of the
most important defense mechanisms of our body to prevent initial plaque
formation. RCT is a mechanism through which free and esterified cholesterol from
extrahepatic (peripheral) tissue are effluxed to HDL, travel to liver, and a) get
secreted as a component of hepatobiliary salt, b) get reabsorbed in small intestine
as a secretory component in bile or c) get excreted via feces (43, 44). RCT from
lipid-laden foam cell macrophages are of particular interest because of its
atheroprotective role. Free cholesterol is utilized by cells for the generation or
repairment of plasma membrane and for the synthesis of hormones by
steriodogenic organs. Excess of cholesterol is highly toxic to cells as they cannot
catabolize cholesterol. However, in macrophages excess of cholesterol can be
esterified into CE and deposited (45). Macrophages and other peripheral tissues
efflux excess cholesterol to extracellular acceptors via a number of mechanisms.
Neutral sterol that is excreted via feces is derived mostly as a by-product of
cholesterol and bile salt synthesis in liver. Cholesterol effluxed from macrophages
contributes relatively small amount to this free cholesterol pool. From liver
cholesterol is delivered to intestine as a component of bile and bile salts and in the
intestine cholesterol is reabsorbed. Unabsorbed cholesterol along with other
neutral sterols gets excreted in feces (46).
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HDL and Apolipoprotein A-I:
The heterogeneous lipoprotein HDL contains almost equal amounts of lipid
and protein. Functional HDL is characterized by high hydrated density (1.063-1.21
g/ml), elevated protein content and small size (5-17 nm) (47). In the total pool of
HDL, the content of lipid, apolipoproteins and enzymes vary significantly resulting
in a great diversity in HDL population with different shape, size, density,
electrophoretic mobility, charge and antigenicity (48). Heterogeneity of HDL is
determined by its apolipoprotein contents, especially by Apolipoprotein A-I (apoAI) conformation. ApoA-I is the major structural apolipoprotein in HDL, constituting
up to 70% of the total protein content. The amphipathic helical structure of apoA-I
allows apoA-I associated HDL to switch between discoidal and spherical shape
under different stages of cholesterol uptake. Ultracentrifugation of HDL gives rise
to two major fraction-i) less dense, larger HDL2 (1.063-1.125 g/ml) population and
ii) more dense, smaller HDL3 (1.125-1.21 g/ml) population (49). Generally smaller
HDL3 is considered to be more effective in inducing cholesterol efflux, shows better
anti-oxidative and anti-inflammatory properties than larger HDL2. However, a very
elevated level of HDL3, a condition which can be associated with impaired HDL
maturation and hepatic delivery of cholesterol, can potentially increase the risk of
cardiovascular diseases (50).
The extracellular cholesterol acceptor involved in RCT is essentially HDL in
different forms. Interaction between lipid-free or lipid-poor apoA-I along with ATPbinding cassette transporter A1 (ABCA1) initiates the efflux of phospholipids and
unesterified cholesterol from the cells. Monomolecular apoA-I, which is
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synthesized by intestine and liver becomes lipidated during this process to form
pre-β migrating discoidal complex. Pre-β migrating nascent HDL contains at least
two molecules of apoA-I, bilayer of phospholipids and little unesterified cholesterol
(Fig. 5). Nascent HDL delivers a portion of its unesterified cholesterol content to
liver and rest of the free cholesterol is esterified by the action of lecithin: cholesterol
acyltransferase (LCAT), which is acquired by nascent HDL from blood plasma.
During the process of highly hydrophobic CE accumulation nascent HDL gets
converted into spherical α-migrating mature HDL. CE along with small amount of
triglyceride forms the hydrophobic core of the mature HDL which is surrounded by
monolayer of phospholipids, unesterified cholesterol and apolipoproteins. A
portion of CE gets recycled back as the component of newly formed apoB
containing plasma lipoproteins (LDL and VLDL) with the help of cholesterol ester
transfer protein (CETP) (51, 52) while majority of CE is delivered to liver (Fig. 6)
(53). In liver the majority of the cholesterol gets incorporated as a component of
bile salt and gets secreted in the duodenum to emulsify dietary lipid. A small
amount of cholesterol is secreted into the bile directly and is re-absorbed by small
intestine (54). The non-biliary pathway of RCT involves fecal excretion of neutral
sterols (55).

Mechanisms Involved in RCT:
Cholesterol efflux only from macrophages and not the other peripheral
tissues, are studied as classic RCT model and has significant importance in
atherosclerotic plaque development. Macrophages present on the arterial wall
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have the potential to become foam cells as they take up modified lipoproteins and
apoptotic cells by phagocytosis. Previous studies have indicated that
macrophages take up more free cholesterol than possibly by any other cells and
free cholesterol can induce apoptosis in macrophages (56). As mentioned earlier,
macrophages have two lines of defense against toxicity by excess cholesterol
loading- i) by esterification of free cholesterol, ii) by cholesterol efflux. Cholesterol
efflux from macrophages involves various mechanisms, such as transporter or
receptor associated cholesterol efflux and by passive diffusion.

ATP-Binding Cassette Transporters:
ABCA1 play a major role is efflux of free cholesterol from macrophages to
lipid-poor apoA-I or nascent HDL. ABCA1 is a large integral membrane protein and
like other members of ABC superfamily utilizes ATP as energy source to transport
metabolites including lipids across the membrane. Tall et al (57) suggest that the
membrane domain of ABCA1 binds to apoA-I (57, 58). Close interaction between
ABCA1 and apoA-I causes transfer of cholesterol and phospholipids from the inner
plasma membrane leaflet to the outer one by a flopping mechanism (59). ApoA-I
takes up this cholesterol and phospholipid by absorption and forms nascent HDL
(57). Several other models have been proposed to explain the high affinity of
ABCA1 towards nascent HDL. Nonetheless, the importance of ABCA1 in RCT
mechanism is unquestionable. Tangier disease which is characterized by loss-offunction mutation in both the ABCA1 alleles, shows severe cholesterol
accumulation in peripheral macrophages as well as HDL deficiency. In vivo mice
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models have further established the critical role of ABCA1 in RCT and therefore in
prevention of atherosclerosis (45, 60).
ATP-binding cassette transporter G1 (ABCG1) is the other transporter from
ABC family involved in RCT. However, ABCG1 shows preference for mature HDL
and not for lipid-poor apoA-I. Disruption of ABCG1 expression results into massive
cholesterol deposition in peripheral tissues including macrophages (61). Many
studies suggest that ABCA1 and ABCG1 function cooperatively and the synergistic
action of these two transporters is responsible for the majority of cholesterol efflux
from macrophages (62, 63). As expected, when ABCA1 and ABCG1 were knocked
down simultaneously in the in vitro or in vivo models, cholesterol deposition
increased severely as the amount of cholesterol efflux was decreased. Increase of
atherosclerotic plaque formation and decreased rate of RCT were far more evident
in the cases of dual knock down than the observed in the absence of either of the
transporters. ABCA1 and ABCG1 are regulated by liver X receptors (LXRα and
LXRβ) which in turn are strongly regulated by cholesterol levels in plasma (64, 65).

Role of SR-B1 in RCT:
Scavenger receptor class B type 1 (SR-B1) is a cell-surface HDL receptor
which is known to promote cholesterol efflux to mature, spherical α-HDL rather
than to nascent HDL. Previous studies suggest that the conformation of apoA-I in
HDL is a strong determinant of SR-B1/ HDL interaction (66). Other studies showed
SR-B1 mediated free cholesterol efflux is also dependent on the phospholipid
content of the HDL. SR-B1 mediated cholesterol efflux is markedly increased to
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the HDL enriched with phosphatidylcholine while HDL enriched with sphingomyelin
facilitates SR-B1 mediated free cholesterol influx. SR-B1 shows this unique feature
of facilitating the bidirectional movement of free cholesterol between HDL and
cells. The bidirectional movement of cholesterol associated with SR-B1 depends
on the cholesterol concentration gradient between HDL and the plasma membrane
(66, 67). However, SR-B1 might not play a very crucial role in cholesterol efflux
from macrophages like ABCA1 and ABCG1 (68) and more investigation is needed
to fully understand the importance and therapeutic value of SR-B1 in cholesterol
efflux from atherosclerotic foam cells.
On the other hand, expression of SR-B1 in liver is extremely crucial for HDL
metabolism and the maintenance of cholesterol homeostasis. As mentioned
earlier, SR-B1 facilitates selective uptake of cholesterol from HDL (and other
lipoproteins) without the degradation of the HDL particle. SR-B1 enables the
delivery of free, unesterified cholesterol from plasma HDL to liver and
steroidogenic tissues by a two-step selective uptake mechanism which also
facilitates the recycling of HDL particles (66). In liver and other tissues HDL binds
to SR-B1 and cholesterol is efficiently transferred to the cells by diffusion into the
plasma membrane (69). As expected, overexpression of hepatic SR-B1 is
associated with lower plasma HDL-cholesterol level and increased content and
transport of cholesterol into the bile from liver (66).
The diffusion model of RCT proposed by Johnson et al (70), postulates that
cholesterol is desorbed from the cell membrane by a spontaneous process and is
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taken up by HDL molecules. This pathway between the cell membrane and
acceptor molecule involves diffusion of cholesterol in the aqueous phase (70, 71).

Current Approaches to Study and Improve RCT:
RCT is known to be inversely related with the risk of atherosclerotic plaque
development and cardiovascular diseases. For over a decade efforts have been
made to quantify RCT and optimize it as a parameter to understand, predict and
treat the cardiovascular diseases better. Initially in vivo model for RCT was
developed using mice model. Modified LDL labeled with 3H-cholesterol was utilized
to generate macrophage foam cells and these foam cells were injected
intraperitoneally in the recipient mice. Plasma and feces samples were collected
from these mice at various time points during the experimental duration and the
fraction of injected 3H-cholesterol recovered in the feces was considered as the
amount of cholesterol undergoing RCT in a given time starting from macrophages
(39, 72). For several years this technique has been used to investigate the effect
of different inhibitors or enhancers on various transporter mediated pathways of
RCT (73). Radioactive (14C) and fluorescently labeled (40) cholesterol have been
used for these studies. Attempts have been made to insert macrophage seeded
polyethersufone hollow fibers intraperitoneally in animals, to mimic the artery, and
to study peripheral cholesterol efflux in vivo (74). However, these methods cannot
be applied to investigate RCT in human subjects. Until recently studying different
components of RCT in human subjects has been invasive, time-consuming
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procedures in which hospitalization of patients over a period of time is required to
administer labeled cholesterol and to collect blood and fecal samples (75, 76).
Recently attempts have been made to develop the in vitro RCT assay which
can be used to measure cholesterol efflux from macrophages in presence of
patients’ serum. Studies by de la Llera-Moya et al (77) and Khera et al (78) used
macrophages loaded with 3H-cholesterol to measure cholesterol efflux capacity in
a large patient population. ApoB depleted serum from healthy volunteers or
patients with different stages of confirmed CAD were used to measure the ability
of serum HDL to induce cholesterol efflux from the macrophages. The study by de
la Llera-Moya et al (77) strongly emphasizes the importance of the functionality of
HDL over the total count of serum HDL. The study by Khera et al (78) which
integrated all the known transporter, receptor and diffusion mediated cholesterol
efflux from macrophages, demonstrated that the ability of HDL to induce
cholesterol efflux was inversely associated with atherosclerosis and CAD. While
this study reinstated the importance of HDL functionality, it also challenges our
understanding of RCT and its relationship with HDL in many ways and makes us
realize that understanding the complexity of RCT is far from over (77, 78).
Recognizing the key components of RCT and the effort to improve them
have been important focus for therapeutic approaches to control atherosclerosis
and CAD. The ex vivo cholesterol efflux assays can be immensely informative
regarding the roles of ABC transporters in RCT or their regulation by LXR. These
data can be used to manipulate and develop target-oriented therapeutic approach
to improve RCT and therefore, reduce the risk of atherosclerosis. Use of LXR
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agonists to enhance ABC transporters can be potentially beneficial if the
undesirable hepatic steatosis induced by these agonists can be minimized as a
side effect. Other approaches explored the possibility to enhance hepatic apoA-I
expression by using small molecules like RVX-208 or via peroxisome proliferator
activated receptor α (PPAR α) agonists. Initial human trial studies involving the
introduction of apoA-I or reconstituted HDL (rHDL) directly in the circulatory system
showed beneficial effects on RCT and the regression of plaques. Some other
therapeutic tactics to improve RCT include oral delivery of apoA-I mimetic peptide,
inhibition of CETP to improve HDL concentration in serum, strategies to increase
SR-B1 mediated hepatic uptake of cholesterol and direct intestinal secretion of
cholesterol (79).

Clinical Relevance of RCT:
The

initial

hypothesis

regarding

linear

correlation

between

HDL

concentration and risk of developing CAD has been questioned for a long time.
The importance of cholesterol efflux is undeniable as several preclinical studies
demonstrated that increased plasma concentration of lipid poor apoA-I not only
improves RCT, but also attenuates or regresses atherosclerotic plaque formation
(80). Based on these observations, novel therapeutic models have been proposed
that will improve the cholesterol efflux capacity of HDL and therefore, HDL
functionality. However, some recent studies have questioned the relevance of RCT
itself. A study by Li et al (81), demonstrated that the cholesterol efflux capacity is
inversely associated with CAD. During this study, initial RCT assays demonstrated
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that the cholesterol efflux capacity associated with apoB-depleted serum was
inversely associated with the risk of CAD in the study group. Surprisingly, when
the same subjects were monitored for the occurrence of CAD for next 3 years, a
clear inverse relationship between the cholesterol efflux capacity and the
prevalence of CAD emerged (81). This unique and highly important study once
again challenges our understanding regarding HDL and its association with CAD.
Nonetheless, cholesterol efflux from peripheral tissues and atherosclerotic plaques
is a highly important target to control CAD and more emphasis should be given to
understand the mechanisms and clinical relevance of RCT.
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Figure 5. Formation of HDL through Various Steps.
ApoA-I is synthesized and secreted by liver and intestine. ApoA-I in the lipid poor form are the best
acceptors of cholesterol and accept cholesterol via ABCA1. Upon accepting cholesterol, it forms
discoidal, pre β-migrating nascent HDL which can further accept cholesterol and phospholipid via
ABCG1, SR-B1 and by diffusion. Esterification of free cholesterol by HDL associated LCAT
generates spherical, α- migrating, mature HDL. Depending on size, HDL can be divided into small,
spherical HDL3 and large spherical HDL2. During RCT, ApoA-I is recycled and excess of ApoA-I is
secreted through the kidney.
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Figure 6. Reverse Cholesterol Transport.
Free cholesterol and phospholipids are effluxed from the peripheral tissues or macrophage
foam cells to HDL via ABCA1, ABCG1, SR-B1 or by diffusion. In HDL, cholesterol is esterified
into CE by LCAT and transported to the liver by selective uptake through SR-B1. From liver
cholesterol gets secreted into the bile as the biliary salt component and reaches the intestine.
Here, cholesterol can get recycled or excreted in the feces. Before reaching the liver, HDL
can trade CE for triglycerides from VLDL or LDL with the help of CETP.
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HDL and Anti-atherogenicity
Anti-atherogenic properties of HDL are mainly attributed, but not restricted
to its capacity to induce cholesterol efflux and reverse cholesterol transport.
Several studies strongly indicated that HDL prevents oxidation of LDL, enhance
endothelial function and repairment (53) and thus prevent the initial steps of fatty
streak formation. HDL is also associated with anti-inflammatory and antithrombotic properties. All properties taken together indicate HDL can prevent
atherosclerotic plaque progression while promoting lesion regression (53). The
diverse functionality of HDL is due to the presence of various apolipoproteins, and
enzymes involved in lipid metabolism, anti-oxidative mechanisms etc.

Antioxidative Effects of HDL:
In 1990 Parthasarathy et al described oxidative modification of LDL can be
reduced or prevented by its co-incubation with HDL (82). Oxidative modification of
LDL involves oxidation of phospholipids, generation of toxic short-chain aldehydes
and oxidation of protein moieties resulting in the generation of mm-LDL. Functional
HDL prevents these modifications by various means.
ApoA-I prevents or delays the formation of mm-LDL by removal of
peroxidized fatty acids and phospholipids. Previous studies further indicate that
HDL can act as a reservoir for peroxidized lipids and deliver them to the liver for
efficient elimination from the body (83). Other apolipoproteins such as apoE, apoAII and apoA-IV are also associated with the anti-oxidant properties of HDL (47).
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Paraoxonase (PON1), an HDL associated enzyme, plays a crucial role as
an anti-oxidant and catalyzes hydrolysis of lipid peroxides, fatty acid peroxides and
hydrogen peroxides to prevent LDL modification (83). PON1, a 45-kDa
glycoprotein hydrolyzes lactones, organophosphate insecticides and nerve gas
agents (84). HDL provides a hydrophobic harbor and stabilizes PON1 after its
secretion from the liver. Association with HDL and interaction with apoA-I is an
essential step for the proper functioning of PON1 (47). It is considered to be a
primary contributory factor to the anti-oxidative property of HDL and protects HDL
from oxidative modification as well. Patients with cardiovascular disorders are
known to have decreased levels and functionally less active PON1 (85). Oxidized
phospholipid mediated monocyte chemotaxis and macrophage activation are
prevented by PON1 (86). Homocysteinylation, a post-translational modification
that can impair normal protein function, is believed to be neutralized by PON1.
Homocysteine thiolactone which causes endothelial injury and initiates fatty streak
formation, is hydrolyzed and detoxified by PON1. Moreover, PON1 is believed to
enhance the production of Lyso PtdCho and polyunsaturated fatty acids by acting
like phospholipase A2. It has been hypothesized that Lyso PtdCho improves the
binding between ABCA1 and HDL and therefore, increases cholesterol efflux (47,
86).
Recent investigations suggest accumulation of oxidized lipids is also
prevented by another HDL associated enzyme LCAT (83). Platelet-activating
factor-acetyl hydrolase (PAF-AH), glutathione selenoperoxidase (GSPx) are the
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other HDL-associated enzymes known to have anti-oxidative properties and
detoxify lipid hydroperoxides to less toxic products (47).

Anti-inflammatory and Other Anti-atherogenic Function of HDL:
As mentioned earlier, HDL inhibits monocyte infiltration in the endothelial
lining induced by Ox-LDL. PON1 and PAF-AH are responsible for this antiinflammatory property of HDL. Additionally, HDL prevents the expression of
cytokine induced cell surface molecules such as VCAM-1, ICAM-1 and E-selectin
(47, 87), which are essential for the initiation of monocyte transmigration and
macrophage differentiation. Therefore, HDL reduce inflammatory response
induced tissue damage. HDL modulates the proper functioning of endothelial cells
and prevents Ox-LDL induced endothelial cell death.
Other anti-atherogenic functions attributed to HDL are anti-apoptotic, antithrombotic, vasodilatory, anti-infectious activities (47).

Dysfunctional HDL and Pro-atherogenicity
Dysfunctionality of HDL has received tremendous attention in the last two
decades. A vast amount of researches have been done to identify the factors
responsible for drastic modifications of structure and composition of HDL and to
address the outcomes associated with HDL dysfunctionality. Acute-phase
response, inflammation and oxidative stress render HDL dysfunctional with highly
adverse consequences.
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Acute and chronic inflammation is known to reduce the concentration of
apoA-I in plasma due to decrease synthesis of apoA-I by the liver. Additionally,
apoA-I is replaced by serum amyloid A (SAA), an acute phase protein, in HDL (47).
As expected, SAA containing small, dense HDL is far less effective to induce
cholesterol efflux. Another highly effective way of impairing apoA-I is known to be
oxidative modifications of certain apoA-I amino acids. Amino acids of apoA-I
undergo chlorination, nitration modifications by myeloperoxidase, an enzyme
secreted by arterial wall macrophages. Oxidized apoA-I fails to induce ABCA1
mediated cholesterol efflux and inhibits LCAT activation (88).
Under inflammatory conditions or oxidative stress, HDL-associated
enzymes often become dysfunctional or inactive. During acute phase response,
PON1 level in plasma is often reduced dramatically or PON1 in HDL is replaced
by SAA (89). Oxidative stress induced PON1 inactivation is known to be
associated with elevated hepatic expression of SR (86). Decreased level of PON1
is closely associated with aging, diabetes and hypercholesterolemia (47).
Even though modifications of apoA-I and PON1 are mostly responsible for
the inactivation of HDL, change in the lipid contents of HDL often leads to HDL
dysfunctionality, other mechanisms contribute significantly to this phenomenon.
During acute phase response and inflammation, CE present in the core of HDL is
often replaced by the triglycerides, resulting in decreased plasma HDL levels. This
characteristic is frequently associated with elevated levels of CETP, which is
responsible for CE transfer from HDL to triglyceride-rich lipoproteins, in the system
(47).
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Dysfunctionality of HDL results in reduced cholesterol efflux, decreased
oxidative protection of LDL by HDL and increased cholesterol influx by
macrophages.

In

summary,

dysfunctional

HDL

increases

the

risk

of

atherosclerosis and cardiovascular diseases by several folds, as opposed to the
atheroprotective functions of native HDL.

Heart Failure and Left-ventricular Ejection Fraction
Heart failure (HF) is one of the costliest and common health problem that is
complex in nature. The morbidity and mortality rate associated with HF is very high.
Population studies show that 30-40% of the patients diagnosed with HF, die within
a year while 60-70% of the mortality happens within 5 years. HF happens following
the gradual and severe muscle weakness/ stiffening in the heart and inefficient
pumping of the blood. As the muscle weakness progresses, the organs and
peripheral tissues receive less amount of oxygenated blood and the pressure in
the heart gradually increases.
Ejection fraction (EF) refers to the percent of the total amount of blood in
the left ventricle, which is pumped out with each heartbeat. A normal heart's EF
varies between 55-70% and EF below 40% is a strong indicator of HF. EF 60
indicates that 60% of the total amount of blood from the left ventricle is pumped
out with each contraction. Patients with EF below 35% are at a very high risk of
life- threatening irregular heartbeats which can lead to sudden cardiac arrest and
death. There are 2 types of HF associated with EF: i) Systolic HF or systolic left
ventricular dysfunction: it is characterized by low left-ventricular EF and less
32

efficient left ventricular contraction resulting in reduced circulation of oxygenated
blood throughout the body, ii) diastolic HF or HF with preserved left ventricular (LV)
function: it is characterized by normal left-ventricular EF and normal contraction,
but irregular ventricle relaxation resulting in reduced inflow of blood in the heart.
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CHAPTER 2:
NOVEL TECHNOQUE FOR GENERATING MACROPHAGE FOAM
CELLS FOR IN VITRO REVERSE CHOLESTEROL TRANSPORT
STUDIES
Introduction:
Increased plasma LDL, an important risk factor for atherosclerosis, leads to
its sub-endothelial accumulation. In the intima LDL undergoes several structural
and physiological modifications, mediated by oxidation, denaturation, by enzyme
actions or by self-aggregation (32, 90-93). Enhanced uptake of modified
lipoproteins by macrophages involves at least two crucial scavenger receptors,
namely SR-A1 and CD36 (27, 94). In addition, fluid phase pinocytosis of LDL has
been suggested to result in foam cell formation (95). Eventually, lesion progression
and plaque rupture result in platelet aggregation and the formation of thrombus,
which can lead to heart attack or stroke (96). Changes in lifestyle, diet and physical
exercise are known to cause regression of atherosclerosis (8).
RCT is a mechanism through which cholesterol from peripheral tissues,
especially from macrophage-rich plaques, are effluxed to apoA-I/ HDL, and then
transferred to liver for disposal (51, 73, 97). It is currently believed that cholesterol
efflux capacity of HDL, and not the HDL cholesterol level, has positive correlation
with anti-atherogenicity (98). However, recent studies by Hazen and associates
showed a remarkable association of RCT with increased risk for myocardial
infarction, stroke, and death. Although RCT assay at the time of sample collection
indicated cholesterol efflux activity from macrophages to apoB-depleted serum, as
cholesterol acceptor, was inversely associated with risk of prevalent CAD (81),
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when subjects were followed for three years a positive correlation between
increased cholesterol efflux and increased CAD was observed. Regardless of the
implications of RCT, it is obvious that RCT is an important phenomenon that
requires not only further investigations but also more efficient methods. Cholesterol
efflux from peripheral tissues is promoted by transporters, ABCA1 and ABCG1
(98). RCT also involves uptake of free and esterified cholesterol by hepatic HDL
receptor SR-B1 (99).
HDL not only acts as an acceptor for plaque cholesterol (100) but also has
been suggested to have several anti-atherogenic functionalities, such as antioxidative, anti-inflammatory and anti-thrombotic (53, 87, 101) properties. Oxidation
of HDL renders it “dysfunctional” (47, 88) and this dysfunctionality has been
suggested to be an important factor in the control of atherosclerosis. Previous
studies showed that oxidation of apoA-I impairs the efflux of cholesterol, and
thereby RCT (102).
The currently available technique to study RCT in vitro involves the use of
macrophage foam cells generated by incubation with cholesterol labeled Ac-LDL.
Macrophages incubated with radiolabeled Ac-LDL are used as foam cells to study
RCT with respect to HDL heterogeneity (103) and to investigate the role of ABCA1
in RCT (39, 77). In recent times, a novel approach has been taken for highthroughput cholesterol efflux studies. Macrophages incubated with radiolabeled
free cholesterol were utilized to study cholesterol efflux in presence of serum from
human subjects (78, 81). Fluorescently labeled cholesterol (NBD-cholesterol),
which has the NBD probe attached to alkyl chain of cholesterol (104), has been
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used for several in vitro RCT studies. This method has been extended to study
RCT in an in vivo model (74). Foam cells loaded with radiolabeled Ac-LDL are
injected intraperitoneally in animal models, then distribution of labeled cholesterol
in plasma, liver and feces were followed and measured (40, 73). To understand
and evaluate the functionality of HDL, a speedier and more reliable assay needs
to be developed.
The current methods of labeling Ac-LDL with radioactive or fluorescent tags
suffer from major deficiencies. First LDL has to be isolated from suitable donors
and Ac-LDL needs to be prepared. These lipoproteins are inherently unstable and
their shelf life is limited. Our previous studies have demonstrated that LDL
undergoes oxidation even during the centrifugation involved in its preparation (90).
Longer dialysis and other steps also promote oxidation and such particles have to
be stored with Ethylenediaminetetraacetic acid (EDTA) or other additives.
Acetylation involves toxic chemicals, such as acetic anhydride, and additional
dialysis

steps

are

involved

in

its

isolation.

The

incorporation

of

radioactive/fluorescent tags involves physical adsorption methods and yet another
purification step to remove unincorporated tracers. In addition, there is variability
in the extent of cholesterol incorporation into different preparations of Ac-LDL that
might offer inconsistent information regarding RCT when cholesterol efflux data
from different patients are compared.
Thus, there is a need for an efficient method for incorporation of cholesterol
into macrophages. Past studies from our laboratory demonstrated that a highly
non-polar molecule, β-carotene, could be very efficiently solubilized using Lyso
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PtdCho as a natural “detergent”. The resulting solution was optically clear, stable
and provided an opportunity to enrich cellular β-carotene in a concentrationdependent manner (105). In this study, we use a similar technique to incorporate
cholesterol or CE into macrophages to generate foam cells. Lyso PtdCho is very
efficiently utilized by macrophages by different ways: a) an acyltransferase
reaction yields Phosphatidylcholine (PtdCho) from lyso, b) lyso phospholipase
cleaves the acyl ester bond and removes the detergent nature of Lyso PtdCho,
and c) inter molecular trans-esterification reaction creates a molecule of PtdCho
and glycerophosphorylcholine (106, 107). In contrast, macrophages esterify
cholesterol and accumulate CE efficiently (108). Thus, while Lyso PtdCho would
be “de-toxified”, CE will accumulate. This process also could be considered
biological as Ox-LDL has been suggested to be involved in foam cell formation,
and contains substantial levels of Lyso PtdCho (109, 110).
NBD-cholesterol has been previously used in several studies related to
uptake, metabolism and HDL-mediated efflux in primary hepatocytes and
fibroblasts (38, 111). In recent years NBD-cholesterol has become a significant
tool to study cholesterol metabolism because it closely mimics the behavior of
cholesterol regarding metabolism and intracellular trafficking (37). In the present
study NBD-cholesterol along with a 3H-cholesterol have been used as the analogs
for cholesterol to demonstrate Lyso PtdCho mediated cholesterol loading, foam
cell development and HDL-induced cholesterol efflux.

37

Materials and Methods:
Reagents:
RPMI 1640, Advanced DMEM (ADMEM), fetal bovine serum (FBS), sodium
pyruvate, L-glutamine, penicillin-streptomycin (PS), 1X phosphate buffer saline
(PBS), NBD-cholesterol were bought from Invitrogen Life Technologies (Carlsbad,
CA). Cholesterol, Lyso PtdCho from egg yolk, oleic acid, 0.9% saline, fucoidan,
polyinosinic acid, 4-dimethylaminopyridine and silica gel matrix for thin layer
chromatography (TLC) separation were purchased from Sigma-Aldrich (St. Louis,
MO). Chloroform, methyl alcohol, hexane, diethyl ether, acetic acid isopropyl
alcohol and ethyl alcohol were purchased from VWR international (Randor, PA).
[1, 2- 3H (N)] cholesterol, [1-14C] Oleic acid, [methyl-14C] Choline chloride were
purchased from American Radiolabeled Chemicals (St. Louis, MO). Oil red O was
purchased from Fisher Scientific (Hampton, NH) and oleic anhydride from Santa
Cruz biotechnology (Dallas, TX).

Cell Culture:
RAW 264.7 macrophages were cultured in RPMI 1640 medium containing
10% FBS, 1% PS, 1% sodium pyruvate and 1% L-glutamine. Cells were seeded
at 1.2 X 106/ ml density and incubated at 37° C in a 5 % CO2 incubator to reach
65-70% confluence overnight. For the experiments involving foam cell
development RPMI 1640 with 0.1% Lipoprotein deficient serum (LPDS) was used
as incubation medium. Swiss Webster mice were purchased from Charles River
(Wilmington, MA) and used to collect peritoneal macrophages. Macrophages from
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peritoneal cavity of 10-week old Swiss Webster mice were isolated by peritoneal
lavage using 5 ml cold 0.9% saline, followed by centrifugation. Cells were cultured
under the same conditions as used for RAW macrophages. HepG2 cells were
cultured in ADMEM containing 10% FBS, 1% PS and 1% L-glutamine.

Solubilization of Cholesterol:
Stock solutions of 5 mM cholesterol and 2 mM NBD-cholesterol were
prepared in chloroform. 20 mM Lyso PtdCho stock solution was prepared in
chloroform: methanol (1:1). For a typical reaction 3 µmoles of cholesterol (600 µl
from the stock), 10 nmoles of NBD-cholesterol (5 µl from the stock) and 3 µmoles
of Lyso PtdCho (150 µl from the stock) solutions were mixed together in a test
tube, followed by drying under nitrogen. 1 ml of sterile PBS was added to the dried
content and the mixture was vigorously vortexed for 1-2 minutes. The aqueous
solution was filtered through 0.22 µm filter. The entire procedure was done under
semi-darkness.
In studies with radioactive cholesterol, NBD-cholesterol was substituted
with 3H-cholesterol to give a final specific radioactivity of 5000 disintegration per
minute (DPM)/ nmole of cholesterol.

Synthesis of Fluorescent CE:
2 mg cholesterol, 0.2 mg NBD-cholesterol and 25 mg oleic anhydride were
mixed and dried in a glass tube. 4-dimethylaminopyridine was added to the
reaction mixture as a catalyst for esterification (112) and the whole reaction mixture
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was heated at 80°C for 30 minutes, until the liquid became bright yellow. The
presence of NBD-CE was verified by TLC and later NBD-CE was separated from
the reaction mixture by column chromatography. Purity of NBD- CE was checked
again by TLC.

Isolation and Modifications of Lipoproteins:
Following Institutional Review Board approval, blood was collected in
heparinized tubes from consented healthy donors and stored on ice. Blood was
centrifuged at 3000 rpm for 20 minutes and plasma was separated. Lipoproteins
were isolated from normal plasma by sequential ultracentrifugation using a
Beckman TL-100 tabletop ultracentrifuge (Beckman, Palo Alto, CA) (113). The
isolated lipoproteins were dialyzed against 0.3 mM EDTA in 1x PBS (pH 7.4)
overnight and subsequently filter sterilized. The amount of protein was estimated
using the Folin Lowry method. Lipoprotein sample was subjected to oxidation
immediately after dialysis. Oxidation of lipoproteins was performed using either
5µM copper or myeloperoxidase (MPO) as described previously (114, 115). LDL
was acetylated using acetic anhydride (92). Ac-LDL was dialyzed overnight and
filter sterilized using 0.2 μm syringe filter. Isolated and modified lipoproteins were
stored at 4°C and used within 1 week of preparation.
Tagging Ac-LDL with 3H-cholesterol was done as described previously by
Kritharides et al (116). Ac-LDL and 3H-cholesterol in ethanol were co-incubated
with RPMI containing 1% LPDS for 24 hours at 37°C. This stock reaction mixture
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was diluted to obtain a working solution which contained 10 µg protein/ ml of AcLDL and 0.25 µCi/ ml 3H-cholesterol in RPMI with 0.1% LPDS (116, 117).

Cellular Uptake of Cholesterol:
RAW 264.7 macrophages were seeded in 12- well plate at 1.2X106 cells/ml
concentrations to reach 65-70% confluence overnight. Cells were washed with
warm sterile PBS once followed by 4 hour of incubation with 0.1% LPDS containing
RPMI 1640. After 4 hours these cells were incubated with 40 µl of cholesterol or
CE/ Lyso PtdCho mixed micelle filtrate per ml of medium (equivalent of 120 µM
concentrations of Lyso PtdCho and cholesterol (or CE) each). For each experiment
involving cholesterol (unlabeled and NBD or 3H-cholesterol) / Lyso PtdCho mixed
micelles 40 µM oleic acid was added to the cells during the incubation. Freshly
isolated peritoneal macrophages were seeded in 24 - well plate at 2.5X106 cells/ml
concentrations and used in the same way to demonstrate cholesterol uptake via
cholesterol / Lyso PtdCho mixed micelles. After overnight incubation, cells were
washed with warm PBS twice and images of live cells were taken under
fluorescence microscope (Axio imager, Carl Zeiss AG, Oberkochen, Germany) or
cells were fixed with 10% formalin and stained with Oil red O.

Detection of Foam Cells:
To detect the presence of fluorescent NBD-cholesterol within the cells,
images of live cells were taken with AxioCam MRm (Axio imager, Carl Zeiss AG,
Oberkochen, Germany). RAW 264.7 macrophages were then lysed by incubating
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with 1 ml of methanol at 37°C for 15 minutes. Cell lysates were centrifuged at 3000
rpm for 10 minutes. 100 µl of supernatant was used to measure fluorescence
intensity present within the cells. Fluorescence plate reader (Envision 2014
Multilabel Plate Reader, PerkinElmer, Waltham, MA) was used to measure
fluorescence intensity at emission spectra of 535 nm upon excitation at 475 nm.
Macrophages were also fixed to stain for CE droplets. After washing with
PBS cells were fixed with 10% formalin, made permeable with 60% isopropanol
and stained with Oil red O. Images of foam cells were taken under 10X and 40X
objectives in the light microscope with the Leica DFC295 camera (Leica camera
AG, Solms, Germany). Oil red O stained lipid droplets were further quantified by
elution of the stain followed by absorption measurement with a spectrophotometer.
Stained wells were rinsed with 60% isopropanol very briefly to remove any residual
Oil red O and then dried completely. Stains were eluted with 1 ml isopropanol for
10 minutes at room temperature. After thorough pipetting to ensure complete
elution, 100 µl aliquots were taken in triplicates in a 96-well plate and absorbance
was measured at 500 nm (118).

Quantification of Cholesterol Incorporated in Total Extracted Lipid and in CE
Fraction:
Macrophages were incubated with

3H-cholesterol

labeled Ac-LDL or

cholesterol (unlabeled and 3H-cholesterol) / Lyso PtdCho mixed micelles for 18
hours at 37°C. Lipid extraction was done using the method of Bligh and Dyer (119).
Lipids were dissolved in 50 µl of chloroform and 5 µl of this was utilized directly to
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measure 3H-cholesterol incorporation. This procedure was done in triplicates and
rest of the reconstituted lipid (~ 35 µl) was used for TLC analysis. Lipids were
separated by TLC on silica gel matrix using hexane/ diethyl ether/ acetic acid (30:
6: 0.5; V/V/V) solvent system (120) and visualized with iodine vapor. Spots of CE
from samples incubated with

3H-cholesterol

labeled Ac-LDL or cholesterol

(unlabeled and 3H-cholesterol) / Lyso PtdCho mixed micelles were compared with
CE standard and analyzed for 3H-cholesterol incorporation by liquid scintillation
and luminescence Counters (MicroBeta2 Plate Counter, PerkinElmer, Waltham,
MA). Count per minute (CPM) values obtained for the incorporation of

3H-

cholesterol in total extracted lipid or CE fraction of lipid was converted into nmoles
of cholesterol and represented subsequently.

Incorporation of 14C- Oleic acid in CE within Foam Cells:
To demonstrate the conversion of cholesterol into CE while using
cholesterol/ Lyso PtdCho mixed micelles,

14C-

Oleic acid was introduced during

incubation of cells with cholesterol/ Lyso PtdCho mixed micelles. A stock solution
of 100 mM oleic acid containing 1 µCi

14C-

Oleic acid was prepared. RAW 264.7

macrophages were incubated with either cholesterol/ Lyso PtdCho or CE/ Lyso
PtdCho mixed micelles in presence of 40 µM oleic acid/ ml of medium for 18 hours.
After overnight incubation, cells were washed with warm PBS twice and lipid
extraction was done with methanol / chloroform (2:1) (119). Chloroform-lipid phase
was separated, the solvent was evaporated under nitrogen and the lipids were
reconstituted with chloroform. Lipids were separated and CE was identified as
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described previously. Spots of CE from samples incubated with cholesterol/ Lyso
PtdCho or CE / Lyso PtdCho mixed micelles were compared with CE standard and
analyzed for

14C-

Oleic acid incorporation by autoradiography (Cyclone Plus

Phosphor Imager- PerkinElmer, Waltham, MA) followed by liquid scintillation and
luminescence counting.

Measurement of Lactate Dehydrogenase Activity:
Lactate dehydrogenase (LDH) cytotoxicity assay kit (Catalog number10008882) was purchased from Cayman Chemical (Ann Arbor, MI) and the assay
was performed following the protocol supplied with the kit. In brief, RAW 264.7
macrophages were seeded at 105 -106 density in 96-well plate. After treating the
cells for 18 hours, 100 µl of medium was collected from each of the well and NAD+
(provided with the kit) was added to the medium. Enzymatic activity of LDH
oxidized lactate into pyruvate and converted NAD+ into NADPH and H+. Finally, a
colorimetric reaction between NADPH and H+ and diaphorase (provided with the
kit) produced dark-pink formazan. Formation of formazan was measured at 490520 nm wavelength using a plate-reader (Benchmark Plus Microplate
Spectrophotometer System, Bio-Rad laboratories, Hercules, CA) and LDH activity
per ml of medium was calculated using standard curve. All the treatments were
performed at least in triplicates and repeated four times.
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Hemolysis of Human RBC:
Human blood collected in a heparinized tube was centrifuged at 3000 rpm
for 20 minutes and red blood cells (RBC) was collected from the pellet and washed.
RBC was diluted with 0.9% saline (1:20; vol: vol) and hemolysis in presence of
water was performed to determine the optical density value equivalent to 1 and to
determine the optimum volume of diluted RBC required for the rest of the
experiment. 75 µl of diluted RBC was taken in eight glass tubes and 0, 10, 25, 50,
100, 150, 200 and 250 µM of Lyso PtdCho micelles, cholesterol/ Lyso PtdCho and
CE/ Lyso PtdCho mixed micelles were added to each tube. The volume was made
up to 1 ml by adding PBS and the reaction mixtures were incubated at room
temperature for 15 minutes. Then the reaction mixtures were centrifuged at 2000
rpm for 15 minutes. Without disturbing the cell pellet, 100 µl of supernatant from
each glass tube were taken in triplicates in a 96-well plate and absorbance was
measured at 540 nm.

Synthesis of 14C- Lyso PtdCho and Quantification of Lyso PtdCho Metabolism by
Macrophages:
Synthesis of 14C- Lyso PtdCho was done from 14C- Choline chloride. HepG2
cells were incubated with 5 µCi of 14C- Choline chloride in presence of total growth
medium, ADMEM that contains 4 µg/ ml choline chloride. After 72 hours of
incubation lipids were extracted and were separated by thin layer chromatography
using chloroform/ methanol/ water (65: 25: 3.5; V/V/V) as the solvent system.
PtdCho band was extracted with chloroform: methanol (1: 1) followed by
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reconstitution of dried lipid content with 0.8 ml of PBS. This reconstituted PtdCho
was subjected to enzymatic conversion into Lyso PtdCho by adding 25 µl snake
venom phospholipase A2 (sPLA2) (0.5 units) and 80 µl of 10 mM CaCl2. The
reaction was set at 37°C for 4 hours and the reaction mixture was used to run TLC
using the previous solvent system with Lyso PtdCho and PtdCho as standards.
Lyso PtdCho band from the TLC plate was extracted and was used for further
experiments.
14C-Lyso

PtdCho was mixed with 3 µmoles unlabeled Lyso PtdCho and 3

µmoles cholesterol from the previously described stock solutions. The reaction
mixture was dried under nitrogen and reconstituted with 1ml PBS by vigorous
vortexing. After filtering, 5 µl the micelles were used to measure radioactivity count.
Cholesterol/ Lyso PtdCho (unlabeled and

14C

labeled) mixed micelles containing

at least 5000 CPM/ ml activity (~ 25 µl/ ml of medium) were used to incubate RAW
264.7 macrophages with for 18 hours at 37°C. After overnight incubation lipid
extraction was done by Bligh and Dyer method and reconstituted lipid was used to
run TLC with PtdCho and Lyso PtdCho standards using chloroform/ methanol/
water (65: 25: 3.5; vol: vol: vol) solvent system. Spots corresponding to PtdCho
and Lyso PtdCho standards were isolated from the TLC plate and metabolic fate
of

14C-Lyso

PtdCho was determined by liquid scintillation and luminescence

counters.
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Quantification of Cellular Cholesterol Efflux:
RAW 264.7 macrophages and mouse peritoneal macrophages incubated
overnight with cholesterol/ Lyso PtdCho mixed micelles were washed with PBS
twice and fresh medium was added. Cells were then incubated with 0- 200 µg/ml
of native HDL or 25 and 50 µg/ml of Ox-HDL (MPO or Cu mediated) for 4 hours
and medium was collected to measure fluorescence intensity. After removal of the
medium, RAW 264.7 macrophages were washed with PBS and images under
fluorescence microscope were taken. To measure fluorescence intensity within the
cells, cell lysates were prepared as described before or cells were fixed and
stained with Oil red O to observe CE accumulation.
To study cholesterol efflux, foam cells were also developed using 3Hcholesterol (and unlabeled cholesterol) / Lyso PtdCho mixed micelles. Efflux of 3Hcholesterol in medium upon incubation with HDL was measured by liquid
scintillation and luminescence counters.

Statistical Analysis:
Each experiment was performed more than three times and each
experimental condition was set up in triplicates. All values were presented as mean
± standard deviation. To determine the difference between two groups, unpaired
2-tailed Student’s t–test was applied. Analysis of variance (ANOVA) was applied
with Dunnett’s or Bonferroni’s correction for multiple comparisons using GraphPad
Prism 5.0 software (San Diego, CA). The minimum level of significance in all tests
was p<0.05.
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Results:
Solubilization of Cholesterol in Aqueous Solution in Presence of Lyso PtdCho:
Cholesterol was solubilized in PBS by mixing cholesterol and Lyso PtdCho
together. To determine if Lyso PtdCho could increase the solubility of cholesterol
in PBS, constant amounts of cholesterol, NBD- cholesterol and an increasing
amount of Lyso PtdCho were taken in five glass tubes. After drying, vigorous
mixing and filtering, aqueous solution was made with 1 ml PBS as described in the
methodology. Prepared mixed micelles contained 1 mM cholesterol (200 µl from 5
mM stock) and 5 µM NBD-cholesterol (2.5 µl from 2 mM stock) and Lyso PtdCho
ranging from 0 to 500 µM (0, 2.5, 5, 12.5 and 25 µl from 20 mM stock).
Fluorescence intensity was determined in the clear filtrate. Fluorescence intensity
of the aqueous solution containing only cholesterol and fluorescent cholesterol,
and no Lyso PtdCho was at the background level and increased in the filtrates
containing increasing amounts of Lyso PtdCho (Fig. 7a).
To determine if cholesterol could reduce the solubility of NBD-cholesterol in
PBS in a concentration-dependent manner, increasing concentrations of
cholesterol ranging from 3- 24 µM (0.6, 1.2, 3.6 and 4.8 µl from 5 mM stock) were
taken in four glass tubes. Equimolar concentration of Lyso PtdCho ranging from 324 µM (0.15, 0.3, 0.9 and 1.2 µl from 20 mM stock) was added to the cholesterol
and a constant concentration of 5 µM NBD-cholesterol was taken. Mixed micelles
in 1 ml of PBS were made as described above. The fluorescence intensity of the
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aqueous solution gradually decreased as the concentration of unlabeled
cholesterol used to make mixed micelles increased (Fig. 7b).

Accumulation of Fluorescent Cholesterol in Macrophages:
RAW 264.7 macrophages were incubated with mixed micelles containing
increasing concentrations (0-10 µM) of NBD-cholesterol for 18 hours. Then the
cells were washed with PBS twice and visualized under fluorescence microscope
(Fig. 7c). Macrophages showed concentration- dependent increased accumulation
of NBD-cholesterol in the cytoplasm, which was further confirmed by measuring
the fluorescence intensity in the corresponding cell lysates (Fig. 7d). Fluorescence
intensity in cells incubated with 0.25, 0.5,1, 5 and 10 µM of NBD-cholesterol were
observed to be several folds higher than the background level.

Mixed Micelles Mediated Cholesterol Uptake is a Quick Process:
RAW 264.7 macrophages were incubated with cholesterol (unlabeled and
NBD-cholesterol) / Lyso PtdCho mixed micelles for 0, 2, 4, 6, 12, 18, 24 and 48
hours. Cells for each treatment condition were incubated with 90 µM cholesterol,
300 nM NBD-cholesterol and 90 µM Lyso PtdCho (15 µl of mixed micelles/ 500 µl
of medium). At the end of each time point cells were observed under microscope
(data not shown) and were lysed to quantify fluorescence intensity in the cell
lysates. It was observed that within two hours the fluorescence intensity of the cells
treated with mixed micelles increased significantly from the background level.
Furthermore, fluorescence intensity in cell lysates after treatment for 4 hours
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increased slightly from 2 hours and almost reached a plateau between 4 to 18
hours. However, after a steady increase in fluorescence intensity at 24 hours, there
was a sharp decrease in fluorescence intensity level at the 48 hour time point even
though it was still several fold higher than the background level (Fig. 7e).

Mixed Micelles of Cholesterol in Aqueous Solution are Stable:
Mixed micelles of cholesterol, NBD-cholesterol and Lyso PtdCho in PBS
was prepared as described before and aliquots of the filtrate were stored at room
temperature, at 4°C and -20°C. Fluorescence intensity of the filtrate from each
storing condition was determined at week 0, week 1, week 2 and week 4 from the
storage time. Mixed micelle solution from each temperature was filtered again right
before their use to measure fluorescence intensity or to treat the cells. We
observed that the fluorescence intensity of the solution stored at room temperature
started deteriorating rapidly, while the fluorescence intensity of the solutions stored
at 4°C and -20°C were fairly stable up to four weeks (Fig 8a). Furthermore, the
mixed micelles stored at -20°C for four weeks were used to develop macrophage
foam cells (Fig. 8b). Fluorescent cholesterol accumulation in the macrophages was
documented by taking images under fluorescence microscope and droplets of CE
were identified by Oil Red O staining.
Fluorescent cholesterol accumulation was further quantified by measuring
fluorescence intensity in the cell lysates (Fig. 8c) and the accumulated CE droplets
were quantified by eluting the Oil red O stain (Fig. 8d). Measurement of
fluorescence intensity and elution of Oil red O stain both confirmed the previous
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observations regarding the stability of mixed micelles at different temperatures.
Cells treated with micelles stored at 4°C and -20°C showed almost no change in
NBD-cholesterol or CE droplet accumulation from the starting time point (week 0).
However, there was a sharp decrease in the accumulation of NBD-cholesterol and
CE droplets in cells treated with micelles stored at room temperature.
In order to substantiate the observations regarding the stability of mixed
micelles additional experiments were performed. Mixed micelles were prepared
using cholesterol (unlabeled and 3H-cholesterol) and Lyso PtdCho and filtered
micelles were stored as described in the previous section. Measurements of
radioactivity in the micelles stored at room temperature, 4°C and -20°C were done
at week 0, week 1, week 2 and week 4. Micelles stored under these conditions
were further used to incubate RAW 264.7 macrophages for 18 hours. Each time
before using, the micelles stored at different temperatures were filtered through
0.22 µm filter. Stability of the 3H-cholesterol containing micelles (Fig. 8e) mimicked
the results of micelles containing NBD-cholesterol. More interestingly, cells treated
with 40 µl (per ml of medium) of 3H-cholesterol containing micelles stored at room
temperature showed steadily decreasing incorporation of cholesterol in total
extracted lipid (Fig. 8g) as well as in CE fraction (Fig. 8f). Incorporation of
cholesterol in total extracted lipid (Fig. 8g) and in CE fraction (Fig. 8f) remained
almost the same as that of the freshly prepared micelles when cells were treated
with micelles stored at 4°C and -20°C even after four weeks (TLC plate- Fig. 15).
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Mixed Micelles Mediated Cholesterol Uptake does not Cause Cell Cytotoxicity:
Amount of lactate dehydrogenase secreted into the medium during the
incubation of cells with cholesterol (or CE) / Lyso PtdCho mixed micelles was
measured to rule out the cytotoxic effect of the mixed micelles (Fig. 9a). Mixed
micelles contained 3 mM Lyso PtdCho alone, 3 mM cholesterol or CE with
equimolar Lyso PtdCho. Macrophages were seeded in 96-well plate in 1 X 105/well
concentration and after 24 hours were washed with PBS twice and incubated with
120 µl of RPMI containing 0.1% LPDS for 4 hours. Cell were then incubated with
1 µg Ac-LDL per well (bar 2), 50 (2 µl from 3 mM Lyso PtdCho containing mixed
micelles) and 75 µM (3 µl) Lyso PtdCho micelles per well (bar 3-4), 50 (2 µl from
3 mM cholesterol/ Lyso PtdCho containing mixed micelles) and 75 µM (3 µl)
cholesterol/ Lyso PtdCho mixed micelles per well (bar 5-6) and 25 (1 µl from 3 mM
CE/ Lyso PtdCho containing mixed micelles) and 50 µM (2 µl) CE/ Lyso PtdCho
mixed micelles per well (bar 7- 8) for 18 hours. All the treatments were done in
triplicates and at the end of 18 hours 100 µl medium was collected from each well
to measure LDH activity in the sample. In this colorimetric assay pink colored
formazan was measured. Cells incubated with Lyso PtdCho micelles produced
very dark-pink color indicating very high cell lysis; whereas cells treated with
cholesterol or CE/ Lyso PtdCho mixed micelles produced very pale pink color as
was observed in the cells without any treatment. Thus, cells treated with
cholesterol or CE / Lyso PtdCho mixed micelles were devoid of toxicity.
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Cytotoxic Effects of Lyso PtdCho are Greatly Reduced by the Presence of
Cholesterol in Mixed Micelles:
RBC diluted in saline were mixed with Lyso PtdCho micelles or cholesterol/
Lyso PtdCho or CE/ Lyso PtdCho mixed micelles containing 0, 10, 25, 50, 100,
150, 200 and 250 µM of Lyso PtdCho or cholesterol or CE. Cholesterol and CE
contain mixed micelles also had equimolar concentrations of Lyso PtdCho. The
reaction mixture containing Lyso PtdCho micelles showed almost immediate
hemolysis and optical density value of the supernatant of the reaction mixtures
were several folds higher when compared with background. Conversely, reaction
mixture containing cholesterol/ Lyso PtdCho mixed micelles showed almost no
hemolysis even at the end of 15 minutes incubation and optical density value of
the supernatant of the reaction mixtures was barely above the background level.
Nevertheless, the hemolytic properties of CE/ Lyso PtdCho mixed micelles were
in between the other two micelles. At lower concentrations, between 10- 100 µM
CE/ Lyso PtdCho did not cause very significant amount of hemolysis, even though
the amount of hemolysis was higher than that induced by cholesterol/ Lyso PtdCho
mixed micelles. There was a sharp increase in the level of hemolysis in the reaction
mixtures containing more than 100 µM CE/ Lyso PtdCho mixed micelles. Between
150- 250 µM concentrations, levels of hemolysis caused by CE/ Lyso PtdCho
mixed micelles were almost the same as those of Lyso PtdCho micelles (Fig. 9b).
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Lyso PtdCho Component of Mixed Micelles was metabolized into PtdCho:
Cells treated with cholesterol/ Lyso PtdCho (unlabeled and

14C-Lyso

PtdCho) mixed micelles for 18 hours demonstrated that more than 75% of Lyso
PtdCho, provided as the component of mixed micelles was metabolized into
PtdCho (Fig. 9c). The metabolization of Lyso PtdCho to PtdCho was a very quick
process, which took place within 2 hours (data not shown) as demonstrated
previously (121, 122).

Foam Cells are developed by Incubating Macrophages with Cholesterol
Containing Mixed Micelles:
RAW 264.7 macrophages and mouse peritoneal macrophages were
incubated with mixed micelles for 18h. 40 µl of mixed micelles which was used per
ml of medium, contained 120 µM cholesterol (unlabeled), 400 nM NBD-cholesterol
and 120 µM Lyso PtdCho (panel iii and vi), while mixed micelles containing CE (24
µl of CE mixed micelles/ ml of medium) had 72 µM unlabeled CE, 240 nM
fluorescently labeled CE and 72 µM Lyso PtdCho (panel iv and vii) (Fig. 10a). AcLDL (10 µg/ml, panel ii) treated macrophages were used as positive control for all
the foam cell development studies. Macrophages incubated with cholesterol / Lyso
PtdCho micelles were provided with 40 µM oleic acid to aid CE conversion and
accumulation. When observed under the fluorescence microscope, cells treated
with NBD-cholesterol containing mixed micelles showed fluorescent cholesterol
accumulation within the cells. As expected negative control cells (panel i and v)
and cells treated with Ac-LDL (panel ii) did not yield any fluorescent images. To
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ensure the accumulation of fluorescent cholesterol was only within the cells, we
lysed RAW 264.7 macrophages and measured the fluorescence intensity in the
cell lysate. Fluorescence intensity in the cell lysates of negative control was
comparable to that of the background level whereas fluorescence intensity was
much higher in the lysate of cells incubated with mixed micelles (data not shown).
CE droplet accumulation in RAW 264.7 macrophages was demonstrated by
Oil red O staining following the treatment with Ac-LDL, cholesterol/ Lyso PtdCho
and CE/ Lyso PtdCho mixed micelles. Oil red O stain was eluted after the images
were taken. Eluted Oil red O stain which indirectly quantifies the amount of CE
droplets present in the cells was taken in 100 µl aliquots and absorption was
measured at 500 nm. Optical density value of all the three samples matched very
closely and ranged between 0.3-0.4 (Fig. 10b).

Quantity of CE Accumulated in Foam Cells Developed by Ac-LDL Mediated
Uptake or Mixed Micelles Mediated Uptake are Similar:
RAW 264.7 macrophages were treated with 10 µg/ml of Ac-LDL labeled
with 3H-cholesterol or with cholesterol (unlabeled and 3H-cholesterol) / Lyso
PtdCho mixed micelles for 18 hours. Quantification of cholesterol incorporation in
total extracted lipid showed, foam cells developed by Ac-LDL mediated and mixed
micelles mediated uptake contained 22 nmoles and 26 nmoles of cholesterol
(volume of total extracted lipid was 50 µl) respectively (Fig. 10c). Cholesterol
incorporation in the CE fraction of extracted lipid was 1.5 nmoles for Ac-LDL
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mediated foam cell development and 1.8 nmoles for that of mixed micelles (Fig.
10d).

Cholesterol is esterified into CE during Micelle Mediated Foam Cell Formation:
RAW 264.7 macrophages incubated with cholesterol / Lyso PtdCho mixed
micelles were simultaneously treated with 14C- Oleic acid to study the incorporation
of radioactive oleate during the esterification of cholesterol into CE. 40 µM oleic
acid (with 200 pCi radioactivity) / ml of medium was supplied during the incubation
of cells with cholesterol or CE / Lyso PtdCho mixed micelles and after overnight
incubation lipids were extracted using methanol / chloroform (2:1). TLC separation
of the samples from both types of micelle treatments showed distinct spots of CE
when compared with the standard CE spot and these spots were further analyzed
for radioactivity. Before exposing the TLC plate to iodine vapor, radioautograph
image of the TLC plate was taken and image clearly demonstrated much higher
oleate incorporation in cells incubated with cholesterol / Lyso PtdCho micelles (Fig.
10e-insert). This observation was further confirmed when analysis for oleate
incorporation in CE showed that cells incubated with CE / Lyso PtdCho micelles
had a 10-fold percentage decrease in 14C- Oleic acid incorporation in CE compared
to cells treated with cholesterol / Lyso PtdCho micelles (Fig. 10e).

The Uptake of Cholesterol Micelles is Distinct from that of Ac- LDL:
Fucoidan and Polyinosinic acid are ligands for SR-A1 and they reduce or
inhibit the uptake of Ac-LDL by macrophages (123, 124). However, fucoidan or
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polyinosinic acid did not inhibit the accumulation of fluorescent cholesterol or CE
in RAW 264.7 macrophages (Fig. 11a- b). 50 µg/ml of fucoidan and 100 µg/ml of
polyinosinic acid were used separately to block Ac-LDL mediated foam cell
formation. Oil Red O staining demonstrated that macrophages pre-incubated with
fucoidan or polyinosinic acid accumulated very little to no CE droplets when treated
with Ac-LDL. But under the same conditions, macrophages incubated with
cholesterol (or CE) / Lyso PtdCho mixed micelles accumulated plenty of CE
droplets (Fig. 11c).
Quantification of CE droplet accumulation by Oil red O stain elution further
established this observation. While the optical density of stains eluted from cells
treated with Ac-LDL following the pre-incubation with fucoidan or polyinosinic acid
decreased by 2-folds from the positive control, the same pre-incubation had little
or no effects on the CE droplet accumulation in cells treated with cholesterol or
CE/ Lyso PtdCho mixed micelles (Fig. 11d).
The unique nature of foam cell development by mixed micelles was further
established by using 3H-cholesterol labeled Ac-LDL and mixed micelles. Pretreatment of fucoidan and polyinosinic acid decreased the incorporation of
cholesterol both in total extracted lipid and in a CE fraction by 4-folds and 2-folds
respectively in case of Ac-LDL mediated foam cell development. Fucoidan and
polyinosinic acid did not have any effect on the incorporation of cholesterol in total
extracted lipid and in CE fraction (Fig. 17) when foam cell development was
mediated by cholesterol (unlabeled and 3H-cholesterol)/ Lyso PtdCho mixed
micelles (Fig. 11a- b).
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HDL Causes Cholesterol Efflux from Foam Cells:
Foam cells were developed by incubating RAW 264.7 macrophages and
mouse peritoneal macrophages with cholesterol (unlabeled and NBD-cholesterol
or 3H cholesterol)/ Lyso PtdCho mixed micelles and used for the efflux study in
presence of HDL. Foam cells were incubated with 0, 25, 50, 100 and 200 µg/ml of
freshly prepared HDL. After 4 hours medium was collected from each well and
RAW 264.7 macrophages were lysed to measure the presence of NBD-cholesterol
in the medium and in the cell lysates respectively. Fluorescence intensity in the
medium collected from foam cells alone (no HDL) was in the background level and
increased in a HDL-concentration dependent manner (Fig. 13a). A similar
observation was made with respect to cholesterol efflux when mouse peritoneal
macrophages were used (Fig 13a- insert). Inversely the fluorescence intensity in
the lysate of foam cells without HDL incubation was the maximum. Fluorescence
intensity in the lysate of foam cells decreased gradually as the concentration of
HDL in the medium increased (Fig. 13b). Images were taken under fluorescence
microscope after the incubation of foam cells with or without HDL. Reduction in
fluorescence intensity indicated less amount of NBD-cholesterol remained inside
the foam cells when incubated with increasing concentrations of HDL. Study of CE
droplet accumulation by Oil red O staining further confirmed our observations (Fig.
13c).
These results were further validated in the efflux study using 3H- cholesterol.
CPM value for 3H- cholesterol efflux was converted into nmoles and presented
(Fig. 14a). Further analysis showed that 25- 200 µg of native HDL caused
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cholesterol efflux ranging between 10- 25% of cholesterol present in total extracted
lipid (Fig. 14b). Preliminary results indicated that most of the cholesterol in the
medium was associated with intact, reisolated HDL (data not shown).

HDL Mediated Cholesterol Efflux is Quantitatively Similar from Foam Cells
Developed by Ac-LDL and Mixed Micelles:
Foam cells developed by 3H-cholesterol labeled Ac-LDL and cholesterol
(unlabeled and 3H- cholesterol) / Lyso PtdCho mixed micelles were incubated with
0, 25 and 50 µg of native HDL for 4 hours. Quantitatively the cholesterol efflux by
25 and 50 µg of HDL from foam cells developed by mixed micelles were a little bit
higher than that from Ac-LDL derived foam cells (Fig. 14c). However, when the
percentage of cholesterol efflux was calculated with respect to cholesterol present
in total extracted lipid, the efflux rate was very similar. Incubation with 25 and 50
µg of HDL caused 2- fold and 3- fold induction in cholesterol efflux from foam cells
developed from either method of cholesterol loading (Fig. 14d).

Ox-HDL Fails to Cause Cholesterol Efflux:
Cholesterol efflux from foam cells were compared in presence of 25 µg and
50 µg native HDL and MPO and Cu mediated Ox-HDL. Cholesterol efflux was
documented by measuring the fluorescence intensity in medium after incubation
of foam cells with 25 µg and 50 µg native HDL and Ox-HDL. Even though Cu OxHDL caused some cholesterol efflux, 25 µg and 50 µg native HDL induced much
higher cholesterol efflux when compared to that of Ox-HDL counterparts (Fig. 13d).
As seen in the figure MPO mediated oxidation of HDL was more effective at
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inhibiting cholesterol efflux than copper mediated oxidation. Cholesterol efflux in
presence of Ox-HDL was further confirmed by using NBD-cholesterol loaded
mouse peritoneal macrophages (Fig. 13e) and 3H- cholesterol loaded foam cells
(data not shown).

Discussion:
In this study, we demonstrated for the first time that macrophage foam cells
can be developed using micellerized cholesterol or CE. The foremost challenge to
incorporate cholesterol in cells is obviously its high hydrophobicity. The amphiphilic
property of Lyso PtdCho, which is also a natural detergent, was utilized to form
mixed micelles and to solubilize cholesterol and CE (unlabeled and fluorescently
labeled) in PBS. A previous study has demonstrated that Lyso PtdCho could form
stable, soluble complex with equimolar cholesterol (125) and this technique has
been modified successfully to solubilize β-carotene in aqueous solution (105).
Augé et al (105) further demonstrated that solubilized β-carotene could be utilized
for cellular enrichment of β-carotene in vitro. In the present study, increasing
amounts of cholesterol (unlabeled and NBD-cholesterol) were successfully
solubilized in PBS by gradually raising the concentration of Lyso PtdCho in the
mixed micelles. Solubility of NBD-cholesterol was demonstrated directly by
measuring the fluorescence intensity of the aqueous solution. We validated the
solubility of cholesterol in aqueous solution indirectly by reducing the solubility of
NBD-cholesterol in a cholesterol concentration-dependent manner. As the
concentration of cholesterol provided to make mixed micelles was gradually
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increased, while keeping the concentration of NBD-cholesterol constant, the
fluorescence intensity of the aqueous solution was decreased in a concentration
dependent manner. RAW 264.7 macrophages were loaded with NBD-cholesterol
and unlabeled cholesterol in a concentration-dependent manner and fluorescently
labeled cholesterol enriched foam cells were developed. Foam cells were
successfully generated by using mouse peritoneal macrophages as well. We also
observed that mixed micelle mediated NBD-cholesterol uptake is a very rapid
process and cells were enriched with NBD-cholesterol as quickly as within 2 hours
continuing up to 24 hours. Nonetheless, there was a sharp decline in the
fluorescence intensity level at 48 hours which was due to detachment of many cells
as a result of over-confluence.
It would be worth noting that previous studies demonstrated that NBDcholesterol has a higher aqueous solubility than cholesterol and might not truly
represent the uptake and efflux of cholesterol (37). Higher solubility of NBDcholesterol has been utilized for uptake studies by directly incubating cells with
NBD-cholesterol in ethanol solution (37, 104). The influence of higher solubility of
NBD-cholesterol in the results of cholesterol uptake and efflux studies was ruled
out by using 3H-cholesterol, a more widely used cholesterol analog to repeat the
key experiments. Recently, Khera et al (78) and Li et al (81) utilized macrophages
labeled with free radioactive cholesterol for high-throughput cholesterol efflux
study. The enrichment of macrophages with free 3H-cholesterol or 14C-cholesterol
was done by incubating cells with free radioactive cholesterol for 24 hours.
However, the goal of our present study was to develop foam cells enriched with
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cholesterol and CE, not just with fluorescent or radiolabeled cholesterol, by a
novel, reproducible and quick technique. Therefore, Lyso PtdCho micelle mediated
cholesterol delivery was a more suitable approach to solubilize and to ensure the
delivery of highly hydrophobic cholesterol and CE to the cells. Besides, we
documented that the free cholesterol delivered by micelles gets esterified to CE
and produces CE droplet enriched foam cells. It is also to be noted that cellular
cholesterol efflux is also accompanied by cellular phospholipid efflux. As noted in
our studies, Lyso PtdCho is efficiently converted to PtdCho and thus would provide
the PtdCho needed for efficient efflux. It remains to be established whether the
fluorescence/ radioactivity of both cholesterol and PtdCho are associated with HDL
fraction in the medium. Our preliminary results (data not shown) suggests that
most of the fluorescence in the medium is associated with isolated HDL after
incubation with foam cells containing NBD-cholesterol.
Incorporation of

14C

oleate was studied to ascertain that esterification of

cholesterol into CE is indeed the source of lipid droplets seen inside the foam cells
upon incubation with cholesterol / Lyso PtdCho micelles. Cells incubated with
cholesterol / Lyso PtdCho micelles yielded the CE band comparable to one from
CE / Lyso PtdCho micelle treated cells, upon TLC separation (Fig. 16).
Nonetheless, cholesterol / Lyso PtdCho micelle treated cells showed very high 14C
oleic acid incorporation, while CE / Lyso PtdCho micelle treated cells had a 10-fold
reduction in oleate incorporation. This demonstrated that cholesterol / Lyso PtdCho
mixed micelles generated foam cells, which would be physiologically relevant as
cholesterol was esterified into CE and appeared as lipid droplets during Oil red O
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staining. For all the experiments involving cholesterol (unlabeled and NBD or 3Hcholesterol) / Lyso PtdCho micelles, cells were incubated with 40 µM oleic acid
along with the micelles. Oleic acid was supplied to facilitate the esterification of
cholesterol into CE and has been used in many studies to follow Ac- LDL uptake.
Lyso PtdCho is known to induce cell lysis due to its detergent like properties
and causes cell lysis by breaking down the intact cell membrane (125-127). It was
observed in the current study that Lyso PtdCho alone is highly soluble in PBS and
caused massive cell death. Cell lysis was confirmed by measuring secretion of
LDH in medium upon incubation of cells with Lyso PtdCho micelles. However, cell
morphology was not affected by the incubation with cholesterol/ Lyso PtdCho
mixed micelles, as clearly demonstrated in Fig. 10a (panel iii). We also
demonstrated that red blood cells were resistant to lysis when increasing
concentrations of cholesterol were present along with Lyso PtdCho. This
observation was not surprising as the work of Rand et al (125) explained that stable
complex

between

equimolar

cholesterol

and

Lyso

PtdCho

causes

a

conformational change in micelle formation, leading to reduction in the
destabilizing and lytic effects of Lyso PtdCho. The reduced lytic effects of
cholesterol/ Lyso PtdCho mixed micelles were clearly established by its reaction
with RBC. Incubation of RBC with Lyso PtdCho micelles for 15 minutes, lysed RBC
releases hemoglobin in the aqueous solution, while the same reaction with an
equivalent amount of cholesterol/ Lyso PtdCho mixed micelles had very little to no
cell lysis. Nonetheless, CE/ Lyso PtdCho mixed micelles induced more cell lysis
causing increased secretion of LDH (data not shown) in the medium and
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hemoglobin in the aqueous solution when compared with that of cholesterol/ Lyso
PtdCho. One possible explanation could be that CE does not cause conformational
changes as cholesterol does during mixed micelle formation and thus CE is less
effective in reducing the lytic effects of Lyso PtdCho. After this initial observation,
reduced volume of CE/ Lyso PtdCho mixed micelles was used to enrich
macrophages with CE. Lytic effects of Lyso PtdCho micelles were clearly in effect
even with the concentration as low as 10 µM of Lyso PtdCho, while presence of
CE up to a concentration of 100 µM CE has greatly reduced this lytic effect.
The advantage of using Lyso PtdCho as a membrane fusion agent to deliver
cholesterol to cells is two-fold as Lyso PtdCho is metabolized by cells into PtdCho
(an acylation reaction) and glycerophosphorylcholine (a transesterification
reaction) (121) as previous studies demonstrated this conversion using various cell
lines including macrophages (122). The quick metabolism of Lyso PtdCho by cells
ensures successful cargo delivery to the cells without influencing RCT. We
observed that more than 75% of Lyso PtdCho, delivered as mixed micelles, was
metabolized into PtdCho within 2 hours of incubation of cells with cholesterol/ Lyso
PtdCho (unlabeled and 14C- tagged) mixed micelles.
We have further established that micellerized CE uptake is uniquely
distinguished from Ac-LDL uptake. SR-A1 is actively involved in Ac-LDL binding
and Ac-LDL mediated uptake of cholesterol (123). We have used fucoidan and
polyinosinic acid, known ligands for SR-A1 (124) to inhibit the binding of Ac-LDL
to SR-A1. As expected fucoidan and polyinosinic acid prevented the Ac-LDL
mediated foam cell formation, greatly inhibited the incorporation of 3H-cholesterol
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in total extracted lipid and in the CE fraction of lipids in Ac-LDL treated cells.
However, SR-A1 ligands had no effects on cholesterol or CE/ Lyso PtdCho mixed
micelle mediated cholesterol delivery and the accumulation of NBD-cholesterol
remained unaffected. Additionally, fucoidan and polyinosinic acid had no inhibitory
effects in the incorporation of 3H-cholesterol in total extracted lipid and in the CE
fraction of lipids when macrophages were incubated with cholesterol/ Lyso PtdCho
mixed micelles. Thus the micelle mediated cholesterol or CE delivery utilizes the
membrane fusion property of Lyso PtdCho, making this foam cell development
technique novel and unique. Furthermore, the universality of micelle mediated
delivery was established by developing cholesterol enriched hepatocyte, HepG2
cells (data not shown).
Currently the development of foam cells, used to study RCT, typically
involves isolation and acetylation of LDL, followed by incorporation of radiolabeled
cholesterol. Isolation of LDL is a tedious process and LDL is prone to be oxidized
automatically during the isolation process (90). Isolation and acetylation of LDL
can vary qualitatively from one preparation to another, resulting in the induction of
inflammatory responses in animal models. Most importantly, Ac-LDL preparations
are not stable and cannot be stored for a long time. In our present study we have
established that cholesterol or CE/ Lyso PtdCho mixed micelle preparation is
functionally stable at 4°C and -20°C up to one month while mixed micelle
preparation stored at -20°C is stable for even longer time (data not shown).
Furthermore, mixed micelle preparation stored at -20°C for one month was used
to develop macrophage foam cells, which were qualitatively similar to those
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developed with freshly prepared mixed micelles. Quantitative analysis of foam cells
developed with mixed micelles stored at 4°C and -20°C up to one month revealed
storage time did not affect the accumulation of NBD-cholesterol, CE droplets or
incorporation of 3H-cholesterol in total extracted lipid and in the CE fraction of the
lipid. Extraction of lipids from the mixed micelle preparation stored at 4°C and 20°C for several weeks followed by analysis from TLC separation showed no
decrease in Lyso PtdCho and cholesterol content (data not shown).
We also observed that mixed micelle mediated cholesterol loading was
highly reproducible and the amount of cholesterol incorporated in the total
extracted lipid always ranged between 25-27 nmoles when cells were incubated
with cholesterol (unlabeled and 3H-cholesterol) / Lyso PtdCho mixed micelles (data
not shown). The same treatment resulted in the incorporation of 1.5- 1.8 nmoles
of cholesterol in CE fraction of the lipid when the experiment was repeated five
times or more (data not shown).
Foam cells developed by using cholesterol/ Lyso PtdCho mixed micelles
were efficiently used to study cholesterol efflux. Increased concentration of HDL
caused a concentration-dependent cholesterol efflux from the foam cells and was
quantified by measuring the amount of NBD-cholesterol in the medium. For the
efflux study, foam cells were also developed using cholesterol (unlabeled and 3Hcholesterol) / Lyso PtdCho mixed micelles and concentration-dependent efflux of
3H-cholesterol

confirmed our observation to that of NBD-cholesterol efflux. It

should also be noted that HDL- mediated cholesterol efflux from foam cells
developed by mixed micelles were quantitatively very similar from foam cells
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developed by Ac-LDL. Various studies have suggested that oxidation of HDL leads
to the loss of its anti-atherogenic property. To determine if the micelle derived foam
cells could be utilized to differentiate between native, functional HDL and oxidized,
dysfunctional HDL, we used equal concentrations of native and Ox-HDL
separately. As we expected Ox-HDL failed to induce any significant cholesterol
efflux from the foam cells. Therefore, we conclude that the foam cells developed
by using cholesterol/ Lyso PtdCho mixed micelles can be potentially used to study
RCT in subjects with or without the background of cardiovascular diseases.
Development of foam cells loaded with fluorescently labeled cholesterol via
mixed micelles mediated technique would be less time consuming and highly
reproducible. Furthermore, these foam cells could be utilized to screen a large
number of human plasma/HDL samples to determine the efficacy of cholesterol
efflux from foam cells or RCT.
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Figure 7. Solubilization of NBD-cholesterol/ Lyso PtdCho Micelles.
Cholesterol (unlabeled) and NBD-cholesterol were mixed together and solubilized in presence of
Lyso PtdCho to form mixed micelles, a) solubilization of cholesterol and NBD-cholesterol in
presence of increasing concentrations of Lyso PtdCho; b) solubilization of NBD- cholesterol is
inhibited by cholesterol in a concentration-dependent manner; c) concentration-dependent
increased uptake of fluorescent cholesterol by RAW 264.7 macrophages, cells were treated with
mixed micelles containing 0- 10 µM NBD-cholesterol, after 18 hrs cells were visualized under
fluorescence microscope (40X objectives); d) cells treated as above were lysed using methanol
and fluorescence intensity was measured using fluorescence plate reader; e) cells were treated
with cholesterol, NBD-cholesterol/ Lyso PtdCho mixed micelles for 0- 48 hrs and fluorescence
intensity in the cell lysate were measured. Values are expressed as mean ± SD (n ≥ 3). ** P < 0.01,
*** P < 0.005 (one-way ANOVA with Dunnett’s multiple comparison test.
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Figure 8. Stability of NBD-cholesterol/ Lyso PtdCho Micelles.
a) Cholesterol, NBD-cholesterol/ Lyso PtdCho mixed micelles were stored at room temperature,
4°C and -20°C for week 0- week 4 and fluorescence intensity of the micellerized NBD-cholesterol
solution stored at different temperatures up to 4 weeks was measured; b) foam cells containing
NBD-cholesterol was developed by incubating macrophages with mixed micelles stored at -20°C
for four weeks; c) cells were treated with fluorescently labeled mixed micelles stored at room
temperature, 4°C and -20°C for week 0- week 4 and fluorescence intensity in the cell lysates were
measured; d) absorbance value of Oil red O stain eluted after staining the cells as treated above;
e) cholesterol, 3H-cholesterol/ Lyso PtdCho mixed micelles were stored at room temperature, 4°C
and -20°C for week 0- week 4 and radioactivity of the micellerized cholesterol solution stored at
different temperature up to 4 weeks was measured (count per minute values were converted into
nmoles of cholesterol and represented); f) cells were treated with 3H-cholesterol labeled mixed
micelles stored at room temperature, 4°C and -20°C for week 0- week 4 and incorporation of
cholesterol in CE fraction were measured; g) incorporation of cholesterol in the total extracted lipid
after the treatment of cells was measured as mentioned above. Values are expressed as mean ±
SD (n ≥ 3). * P < 0.05, ** P < 0.01, *** P < 0.005 (one-way ANOVA with Dunnett’s multiple
comparison test). Significant differences in values for different storage temperatures and timepoints are always compared with week 0 value.
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Figure 9. Foam Cells Were Developed Using Cholesterol or CE (Unlabeled)
/Lyso PtdCho Mixed Micelles Without Inducing Cytotoxic Effects.
a) Lactate dehydrogenase secreted in the medium was used to quantify LDH activity (µU/ml) in
samples treated under different conditions- no treatment, 1 µg Ac-LDL, 50 and 75 µM Lyso PtdCho
micelles or cholesterol/ Lyso PtdCho micelles, 25 and 50 µM CE/ Lyso PtdCho micelles per well.
P values for samples treated with Lyso PtdCho alone were calculated against control (no
treatment), for samples treated with cholesterol or CE /Lyso PtdCho mixed micelles were calculated
against the samples treated with Lyso PtdCho alone. Values are expressed as mean ± SD (n ≥ 3).
*** or ### P < 0.005 (one-way ANOVA with Bonferroni’s multiple comparison test). b) Hemolysis of
human RBC was demonstrated by adding increasing concentrations of Lyso PtdCho micelles,
cholesterol/ Lyso PtdCho or CE/ Lyso PtdCho mixed micelles to constant concentration of RBC
and optical density of the reaction mixture was measured; c) metabolization of 14C- Lyso PtdCho
used as the component of cholesterol/ Lyso PtdCho micelles was demonstrated. Values are
expressed as mean ± SD (n ≥ 3). *** P < 0.005 (2-tailed student’s t-test).

70

Figure 10. Foam Cells Developed Using Mixed Micelles Show Cholesterol
Esterification.
a) RAW 264.7 (panel i- iv) and mouse peritoneal macrophages (panel v-vii) incubated with mixed
micelles for 18 hours showed accumulation of NBD-cholesterol (iii- RAW 264.7 macrophages and
vi- mouse peritoneal macrophages) and fluorescent CE (iv- RAW 264.7 macrophages and viimouse peritoneal macrophages) droplet under fluorescence microscope. CE droplet accumulation
demonstrated by Oil Red O staining. CE droplet accumulation was observed in cells treated with
Ac-LDL (ii- RAW 264.7 macrophages), cholesterol (iii- RAW 264.7 macrophages and vi- mouse
peritoneal macrophages) or CE (iv- RAW 264.7 macrophages and vii- mouse peritoneal
macrophages)/ Lyso PtdCho mixed micelles; b) Oil red O stain from RAW 264.7 macrophages
treated with Ac-LDL and cholesterol/ Lyso PtdCho or CE/ Lyso PtdCho mixed micelles were eluted
and absorbance was measured; c) cells were treated with 3H-cholesterol labeled Ac-LDL or
cholesterol, 3H-cholesterol/ Lyso PtdCho mixed micelles and incorporation of cholesterol in total
extracted lipid was measured; d) incorporation of cholesterol in CE fraction was measured following
the above mentioned treatment; e) cells incubated with cholesterol or CE / Lyso PtdCho mixed
micelles were supplied with 40 µM 14C-oleic acid / ml. Cells incubated with CE / Lyso PtdCho
mixed micelles showed almost 10-fold less 14C-oleic acid incorporation than those treated with
cholesterol / Lyso PtdCho mixed micelles. Insert shows radioautography image of 14C-oleic acid
incorporation in CE fraction of cells as treated above. Values are expressed as mean ± SD (n ≥ 3).
** P < 0.01 (2-tailed student’s t-test).
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Figure 11. Mixed Micelle Mediated Foam Cell Formation is not affected by
Scavenger Receptor Binding Ligands.
a) Macrophages were pre-incubated with either 50 µg/ ml fucoidan or 100 µg/ ml polyinosinic acid,
followed by incubation with cholesterol or CE (unlabeled and fluorescently labeled)/ Lyso PtdCho
mixed micelles for 18 hours. NBD-cholesterol or fluorescent CE accumulation within macrophages
was observed in the cells pre-incubated with fucoidan and polyinosinic acid; b) measurement of
fluorescence intensity in cell lysates from cells treated with fluorescently labeled cholesterol or CE
with or without fucoidan or polyinosinic acid treatment; c) Macrophages pre-incubated with fucoidan
and polyinosinic acid showed very little to no CE droplet accumulation after treatment with Ac-LDL
(i). CE droplet accumulation in macrophages pre-incubated with fucoidan and polyinosinic acid was
observed after incubation with cholesterol (ii) or CE (iii)/ Lyso PtdCho mixed micelles; d) Oil red O
stain was eluted from the cells treated with Ac-LDL and cholesterol or CE/ Lyso PtdCho mixed
micelles with or without the pre-incubation of fucoidan or polyinosinic acid and absorption of Oil red
O stain at 500 nm was measured. Values are expressed as mean ± SD (n ≥ 3). *** P < 0.005 (oneway ANOVA with Dunnett’s multiple comparison test). Significant differences for fucoidan and
polyinosinic treatment are always compared with the respective positive control.
.
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Figure 12. Incorporation of Cholesterol is not inhibited by Pre- incubation
with Fucoidan or Polyinosinic Acid.
a) RAW 264.7 macrophages were treated with 3H-cholesterol labeled Ac-LDL or cholesterol, 3Hcholesterol/ Lyso PtdCho mixed micelles with or without fucoidan and polyinosinic acid preincubation and incorporation of cholesterol in total extracted lipid was measured; b) incorporation
of cholesterol in CE fraction was measured from cells as treated above. Values are expressed as
mean ± SD (n ≥ 3). ** P < 0.01, *** P < 0.005 (one-way ANOVA with Dunnett’s multiple comparison
test). Significant differences for fucoidan and polyinosinic treatment are always compared with the
respective positive control.
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Figure 13. Cholesterol Efflux From Foam Cells in Presence of HDL.
Foam cells were developed using cholesterol (unlabeled and NBD-cholesterol or 3H-cholesterol)/
Lyso PtdCho mixed micelles. Foam cells were incubated with 0- 200 µg/ml of HDL for 4 hours. a)
Medium from NBD-cholesterol containing foam cells (RAW 264.7 macrophages) incubated with
increasing concentrations of HDL showed concentration-dependent increase in fluorescence
intensity. Insert shows mouse peritoneal macrophage derived foam cells incubated with HDL
demonstrating concentration-dependent NBD-cholesterol efflux in the medium; b) fluorescence
intensity in the corresponding cell lysates decreased as the concentration of HDL increased. * P <
0.05; ** P < 0.01, *** P < 0.005 (one-way ANOVA with Dunnett’s multiple comparison test). c)
Fluorescence images and Oil Red O staining showed reduction in CE droplet accumulations in
cells after incubation with HDL; d) foam cells were incubated with 25 and 50 µg/ml of native HDL
and MPO or Cu mediated Ox-HDL. Cholesterol efflux caused by native HDL was much higher when
compared with the same concentration of Ox-HDL. Values are expressed as mean ± SD (n ≥ 3).
*** P < 0.005 (one-way ANOVA with Dunnett’s multiple comparison test). Significant differences for
Ox-HDL treatments are always compared with the corresponding concentration of native HDL. e)
Cholesterol efflux from peritoneal macrophage derived foam cells incubated with 25 and 50 µg/ml
of native HDL and MPO mediated Ox-HDL. Values are expressed as mean ± SD (n ≥ 3). *** P <
0.005 (2-tailed student’s t-test).
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Figure 14. Ac-LDL and Mixed Micelles Mediated Foam Cells Demonstrated
Similar HDL-dependent Cholesterol Efflux.
a) Foam cells developed by incubation with 3H-cholesterol containing mixed micelles showed
concentration-dependent increase in cholesterol efflux when treated with increasing concentrations
of HDL; b) HDL- mediated cholesterol efflux was represented as % of cholesterol incorporated in
total extracted lipid; c) foam cells were developed by incubating macrophages with 3H-cholesterol
labeled Ac-LDL or 3H-cholesterol containing mixed micelles and HDL- mediated cholesterol efflux
was studied using 25 and 50 µg/ml of native HDL; d) HDL- mediated cholesterol efflux represented
as % of cholesterol incorporated in total extracted lipid. Values are expressed as mean ± SD (n ≥
3). ** P < 0.01, *** P < 0.005 (one-way ANOVA with Dunnett’s multiple comparison test).
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Figure 15. Extracted Lipid was separated on TLC Plate and TLC Plate Exposed to Iodine Vapor.
Cholesterol (unlabeled and 3H-cholesterol)/ Lyso PtdCho mixed micelles stored at room temperature, 4° C and -20° C for Week 0,
Week 1, Week 2 and Week 4 were used to incubate RAW 264.7 macrophages for 18 hours. Extracted lipid was used to run TLC
with cholesterol, cholesteryl ester and Lyso PtdCho standards and one of the representative TLC plate was shown here. TLC plate
was cut into eight sections for each sample and radioactivity measurement was taken as shown in the table.
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Figure 16. Extracted Lipid was separated on TLC Plate and TLC Plate Exposed to Autoradiography
Imager Followed by Exposure to Iodine Vapor.
Cholesterol/ Lyso PtdCho and CE/ Lyso PtdCho mixed micelles along with 14C-Oleic acid were used to incubate RAW 264.7
macrophages for 18 hours. Extracted lipid was used to run TLC with cholesterol, cholesteryl ester, oleic acid and Lyso PtdCho
standards. TLC plate was cut into eight sections for each sample and radioactivity measurement was taken as shown in the table.
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Figure 17. Extracted Lipid was separated on TLC Plate and TLC Plate Exposed to Iodine Vapor.
3H-cholesterol

tagged ac-LDL and cholesterol (unlabeled and 3H-cholesterol)/ Lyso PtdCho mixed were used to incubate RAW
264.7 macrophages with or without fucoidan or polyinosinic acid for 18 hours. Extracted lipid was used to run TLC with cholesterol
and cholesteryl ester standards. TLC plate was cut into eight sections for each sample and radioactivity measurement was taken
as shown in the table.
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CHAPTER 3:
PLASMA FROM HEART FAILURE PATIENTS WITH NORMAL
EJECTION FRACTION HAVE BETTER HDL FUNCTIONALITY AS
COMPARED TO SUBJECTS WITH POOR EJECTION FRACTION
Introduction
Population studies from the past few decades have clearly demonstrated
that plasma HDL has an inverse relationship with the progression of cardiovascular
disease. Some of the atheroprotective functions of HDL are associated with, but
not limited to, its role in RCT and the prevention of LDL oxidation (101).
RCT can be considered as the main defense mechanism against
atherosclerotic plaque development. The mechanism of RCT involves efflux of
cholesterol from the peripheral tissue and lipid-laden macrophages to extracellular
cholesterol acceptor HDL, and the transport of cholesterol to liver for recycling or
disposal via excretion. ABCA1 and ABCG1 are the major transporters involved in
the efflux of cholesterol from macrophages. ABCA1 mediated lipid transport
involves lipid-free or lipid-poor form of HDL, which contains mostly apolipoproteins.
The models for ABCA1 associated lipid transport suggest that binding of ABCA1
with apoA-I induces efflux of cholesterol from the plasma membrane. However,
ABCA1 can bind to a wider range of apolipoproteins such as apoA-II, apoA-IV,
apoE and apoC. Lipidation of apolipoproteins with cholesterol and phospholipids
produces pre-β migrating HDL particles which continue to be acceptors of
cholesterol effluxed via ABCA1 (59, 73, 98, 128). ABCG1 mediated cholesterol
efflux mostly involves mature α-migrating HDL and ABCG1 associated pathway
accounts for 6-12% of the free cholesterol efflux from the cell membranes (62).
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Plasma HDL density varies between 1.06- 1.21 g/ml and the population of
human plasma HDL constitutes a heterogeneous group of particles which can be
distinguished based on their size, density, electrophoretic mobility, lipid and
apolipoprotein composition. Mature HDL can be categorized into 2 major
populations based on the separation done by ultracentrifugation, i) large, spherical
HDL2 and ii) small, dense, protein-rich HDL3. Several studies investigating the
characteristics of HDL3 revealed that majority of the apoA-I in the plasma
associated with HDL3 and this sub-fraction of HDL is also enriched with several
anti-oxidant enzymes such as PON1, PAF-AH or lipoprotein associated
phospholipase A2 and LCAT. Thus, HDL3 is believed to play a critical role not only
in RCT but also in the anti-oxidative functions associated with HDL (49, 129).
Additionally, HDL, especially HDL3 is also known to act as an anti-apoptotic factor
and protects macrophages from Ox-LDL induced apoptosis by stimulating
cholesterol efflux (130).
Studies from the last two decades strongly suggested that HDL prevents
the oxidative modification of LDL and Ox-LDL induced cytotoxicity which are the
crucial events to initiate atherosclerotic plaque development (101). Co-incubation
with HDL not only decreased the metal ion or cell induced oxidation of LDL, but
also reduced the uptake of modified LDL by macrophages. HDL acts as a
scavenger for lipid peroxides along with preventing the formation of lipid peroxides
(131, 132). Association of HDL with various enzymes is believed to be responsible
for its anti-oxidative properties. One of the most potent enzymes involved in the
anti-oxidative activities of HDL is PON1. Serum PON1 is a calcium dependent
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esterase, synthesized and secreted by the liver. PON1 catalyzes the hydrolysis of
organophosphates, insecticides, aromatic carboxylic acid esters, carbamates and
nerve gas and produces less toxic products (133). HDL provides stability to this
43-KDa enzyme after its secretion from liver. The affinity of apoA-I to PON1 for
binding is very high and apoA-I is believed to stimulate the lactonase activity of
PON1. Previous studies indicated that PON1 protects LDL from oxidation and
stimulates cholesterol efflux from macrophages (134, 135). Protection of LDL from
oxidation is believed to be mediated by PON1 in 2 separate ways. Firstly, during
the metal ion or cell induced oxidation, PON1 inhibits the accumulation of lipid
peroxides and secondly, PON1 eliminates the pre-formed lipid peroxides (136).
Moreover, PON1 attenuates the uptake of Ox-LDL by macrophages via SR CD36
(134),

prevents

macrophage

cholesterol

biosynthesis

and

cholesterol

accumulation (137). Therefore, PON1 can be considered as the major contributory
factor to the anti-atherogenic properties of HDL. Anti-oxidative activities of HDL
are also associated with the functions of PAF-AH, LCAT, and several
apolipoproteins such as apoA-I, apoA-II, apoA-IV, apoE and apoJ (129).
Modifications of structure and composition of HDL play a crucial role in the
progression of several pathological conditions and the alterations of HDL are often
associated with inflammation, oxidative stress, atherosclerosis and hyperlipidemia.
One of the major modifications that severely affects the proper functioning of HDL
is alteration apoA-I. During acute inflammation, the secretion of apoA-I from the
liver is often decreased or apoA-I on HDL is replaced by SAA (47, 138).
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Previous studies by several groups indicated that the replacement of apoAI by SAA significantly impairs the cholesterol efflux capacity of HDL. Although, the
native HDL present during acute inflammatory response or SAA containing HDL
seemed to bind to macrophages with a higher affinity, they are less effective to
induce free cholesterol efflux from the macrophages under these conditions (138140). Furthermore, it has been observed that the acute phase HDL or SAA
containing HDL promote CE uptake by monocytes and macrophages and thus
enhance the process of foam cell formation (139). Acute phase HDL or SAA
containing HDL also have reduced capacity to bind to hepatocytes and deliver
cholesterol for clearance from the body (141). Therefore, during acute
inflammation or due to replacement of apoA-I by SAA, HDL become proatherogenic as they promote CE influx to peripheral tissues, become less effective
to induce cholesterol efflux from macrophages and demonstrate reduced
association with hepatocytes which is essential for the final steps of RCT. ApoA-I
is also susceptible to oxidation by metal ions in vitro and by MPO enzyme in vivo.
Recently the oxidation of HDL associated with MPO has received a lot of attention.
MPO is a neutrophil granulocyte derived peroxidase enzyme that catalyzes the
formation of hypochlorous acid from chloride ions and nitrogen dioxide radicals by
using hydrogen peroxide and nitric oxide as oxidizing agents. In vitro studies have
showed that MPO catalyzes the chlorination and nitration of specific tyrosine
residues on apoA-I to form chlorotyrosine and nitrotyrosine respectively (142, 143).
Moreover, plasma HDL isolated from patients with CAD revealed higher
concentrations of chlorotyrosine and nitrotyrosine per apoA-I than those present in
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subjects without the history of CAD (144, 145). Oxidation of apoA-I impairs its
ability to induce free cholesterol efflux from macrophages. Previous studies have
suggested chlorination of tyrosine residue 192 on apoA-I disables the strong
association between apoA-I and ABCA1 transporter which is essential for the efflux
of cholesterol to lipid poor or lipid free apoA-I and nascent HDL (88, 142).
Additionally, chlorination of apoA-I prevents the activation of LCAT (88) and thus
oxidation of HDL affects RCT in a 2-fold way. It has also been suggested that
oxidation of apoA-II impairs the antioxidant properties of HDL (102).
HF is one of the most common, disabling and costly public health problem
and is complex in nature. HF is associated with high rate of morbidity and mortality.
Population studies show that 30-40% of the patients diagnosed with heart failure,
die within a year while 60-70% of the mortality happens within 5 years. HF happens
following the gradual and severe muscle weakness/ stiffening in the heart and
inefficient pumping of the blood. As the muscle weakness progresses, the organs
and peripheral tissues receive less amount of oxygenated blood and the pressure
in the heart gradually increases. EF refers to the percent of the total amount of
blood in the left ventricle, which is pumped out with each heartbeat. A normal
heart's EF varies between 55-70% and EF below 40% is a strong indicator of HF.
Our preliminary studies indicated that the peripheral blood (PB) plasma from
the human HF patients with low EF had high levels of Ox-LDL accumulation when
compared with the PB plasma from the HF patients with normal EF. The goal of
this study was to determine if the accumulation of higher amount of Ox-LDL is a
reflection of the quality of the HDL. The quality and the functionality of HDL was
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investigated by performing cholesterol efflux assays with foam cells, generated in
vitro using cholesterol/Lyso PtdCho mixed micelles (28). Additionally, PON1
arylesterase activity of the plasma samples was assessed to evaluate the
functionality of the patients’ HDL as an anti-atherogenic lipoprotein.

Materials and Methods
Reagents:
RPMI 1640, FBS, sodium pyruvate, L-glutamine, PS, 1X PBS, NBDcholesterol and Hank’s balanced salt solution (HBSS) were bought from Invitrogen
Life Technologies (Carlsbad, CA). Cholesterol, calcium chloride (CaCl2),
magnesium chloride (MgCl2), Lyso PtdCho from egg yolk, oleic acid, 0.9% saline
and p-Nitrophenyl acetate (p-NPA) were purchased from Sigma-Aldrich (St. Louis,
MO). Acetone, isopropyl alcohol and ethyl alcohol were purchased from VWR
international (Randor, PA). [1, 2- 3H (N)] cholesterol was bought from American
Radiolabeled Chemicals (St. Louis, MO).

Cell Culture:
RAW 264.7 macrophages were cultured in RPMI 1640 medium containing
10% FBS, 1% PS, 1% sodium pyruvate and 1% L-glutamine. Cells were seeded
at 3 X 105/ 250 µl density in the 48-well plate and incubated at 37° C in a 5 % CO2
incubator to reach 65-70% confluence overnight. For the experiments involving
foam cell development RPMI 1640 with 0.1% LPDS was used as incubation
medium.
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Generation of Foam Cells in vitro:
Foam cells were generated in vitro as described previously (146). Briefly,
RAW 264.7 macrophages were incubated with cholesterol (unlabeled and NBD or
3H-cholesterol)/Lyso

PtdCho mixed micelles for 18 hours in presence of 40 µM

oleic acid.

Human Subjects:
Following the Ohio State University School of Medicine Institutional Review
Board (IRB) approval, blood was collected from 48 patients (consented)
undergoing routine cardiovascular surgery [coronary artery bypass grafting
(CABG), valve repair/replacement (AVR, MVR, TVR: aortic, mitral, or tricuspid
valve replacements) or other open heart surgeries] at The Ohio State University
Medical Center. Simpson’s bi-plane technique was used to determine left
ventricular ejection fractions. Two ml of left ventricular blood (LVB) was collected
by aspirating blood using a 23 gauge needle and 10cc syringe placed through the
ventricular apex. Simultaneously 5 ml of PB was collected from a peripheral
venous line. Blood was collected in heparinized tubes and labeled with number
associated with the study. Plasma was separated immediately after collection by
centrifugation at 3000 rpm for 20 minutes. Isolated plasma were stored at -80°C
for further analysis. No patients had clinical evidence of active ischemia at the time
of blood sampling.
For the control group, peripheral blood was collected from the subjects
undergoing overnight fasting. Blood was collected from the left-hand index finger
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using blood lancet in a heparinized tube and plasma was isolated as described
previously.

Exclusion Criteria:
Subjects who were on antioxidant supplements (vitamin E, C, beta carotene
and lipoic acid) were excluded from the study. All the patients were optimized with
medical management prior to surgery and these included the use of β-blockers,
ACE inhibitors, statins and diuretic therapy. The use of such therapies themselves
could affect the built-up of Ox-LDL. As per the clinical criteria HF subjects not older
than 85 years and EF less than or equal to 70% were included for this study.
For the control group, the subjects were between 30-65 years of age and
did not have any history of HF or never underwent any routine cardiovascular
surgery.

Cholesterol Efflux Study:
Raw 264.7 macrophages were washed with sterile PBS twice after
overnight incubation with cholesterol/Lyso PtdCho mixed micelles. Macrophage
foam cells were incubated with 400 µl of HBSS and 5 µl plasma samples for 4
hours. At the end of 4 hour incubation, HBSS was collected from each well and
efflux of labeled cholesterol was measured. HBSS containing no plasma and
incubated with foam cells (NBD or

3H-cholesterol

background value in the cholesterol efflux experiments.
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labeled) was used for

The HBSS and plasma samples incubated with foam cells containing 3Hcholesterol were collected and efflux of 3H-cholesterol was measured in 100 µl
aliquots using liquid scintillation and luminescence Counters (MicroBeta2 Plate
Counter, PerkinElmer, Waltham, MA). For the cholesterol efflux study involving 3Hcholesterol, CPM value was converted into nmoles of cholesterol and expressed
as the unit of measurement. When the cholesterol efflux study was performed
using NBD-cholesterol containing foam cells, HBSS containing plasma samples
were subjected to de-proteination steps.

De-proteination of Samples:
The HBSS and plasma samples used for cholesterol efflux study involving
NBD-cholesterol was not suitable for direct fluorescence measurement. The high
concentration of protein present in the plasma samples interferes with the
fluorescence measurement and samples have to be subjected to de-proteination..
For the de-proteination procedure, 400 µl of HBSS with or without the plasma
samples were collected in glass test tubes at the end of the 4 hour incubation with
foam cells. 1 ml of ice-cold acetone and isopropyl alcohol (vol: vol, 1:1) was added
to HBSS with or without the plasma samples. The solution mixture was incubated
at 4°C for 30 minutes and centrifuged at 400 g for 10 minutes. Precipitated protein
pellet was visible at the bottom of the glass tube. Acetone: isopropyl alcohol phase
of the supernatant was evaporated under nitrogen gas at 30°C without disturbing
the protein precipitate. After evaporating the organic solvent phase, 100 µl aliquots
of the supernatants were taken and fluorescence was measured using
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fluorescence plate reader (Envision 2014 Multilabel Plate Reader, PerkinElmer,
Waltham, MA). Fluorescence of effluxed NBD-cholesterol was measured at
emission spectra of 535 nm upon excitation at 485 nm.

PON1 Assay:
The plasma PON1 arylesterase activity was measured by following the
method of Jaichander et al (147). Briefly, 10 µl aliquots of human plasma was
incubated with 1 mM p-NPA in 100 µl phosphate buffer with 2 mM CaCl2 and
MgCl2 at 37°C for 30 minutes. The reaction was set up in 96-well plate and the
reaction for each patient plasma sample was set up in triplicates. p-NPA was used
as the substrate for PON1 enzyme activity and the resultant product p-Nitrophenol
conversion was measured at 410 nm.

Statistical Analysis:
Each experiment was performed more than three times and each
experimental condition was set up in triplicates. All values were presented as mean
± standard deviation. Analysis of variance (ANOVA) was applied with Bonferroni’s
correction for multiple comparisons using GraphPad Prism 5.0 software (San
Diego, CA). The minimum level of significance in all tests was p<0.05.

88

Results
PB Plasma from Patients with Lower EF Showed Reduced Cholesterol Efflux:
Foam cells generated with cholesterol/Lyso PtdCho mixed micelles were
used for cholesterol efflux studies in presence of PB plasma from patients. The
patient group with EF >60% showed almost 3-fold higher cholesterol efflux than
the group with EF <40% (Fig. 18). This pattern was observed when the cholesterol
efflux studies were performed with either NBD-cholesterol (Fig. 18a) or 3Hcholesterol (Fig. 18b).

LVB and PB from the Same Patient Showed Different Level of Cholesterol Efflux:
The cholesterol efflux study was done using PB and LVB from the same
groups of patients. As mentioned earlier, the cholesterol efflux assay performed
with PB demonstrated that the group of patients with lower EF showed less
efficient cholesterol efflux when compared with the group of patients with normal
EF. However, the cholesterol efflux studies using LVB from both of these groups
showed very similar cholesterol efflux values [both with NBD-cholesterol (Fig. 18a)
and 3H-cholesterol (Fig. 18b)] and these values were very close to the efflux
pattern observed with the PB plasma of the low EF group. Interestingly, the group
with EF >60% showed higher levels of the cholesterol efflux with their PB plasma
compared to the LVB. In contrast, the group of patients with EF <40% showed
similar levels of cholesterol efflux with both, the PB and LVB blood, and the values
of cholesterol efflux were distinctively much lower than the observed with the PB
plasma of the normal EF group .There was no significant difference between the
89

cholesterol efflux capacity of LVB plasma used from patients with lower and normal
EF.

Plasma Samples with Reduced Cholesterol Efflux Capacity Also Showed Reduced
PON1 Activity:
PB and LVB plasma samples from the same groups of patients were used
to assay plasma PON1 arylesterase activity. Conversion rate of p-NPA to pNitrophenol in a time period of 30 minutes was regarded as measurement of PON1
activity. The results obtained with the PB plasma showed that patients with normal
EF had significantly higher PON1 activity compared to patients with lower EF.
However, similar to the results obtained with the RCT assays, both groups showed
a very similar pattern of PON1 activity when LVB plasma was used. On the other
hand, the comparison of PB and LVB plasma from the same group of patients
showed that PON1 activity was much lower in LVB plasma than in PB plasma in
the group with EF >60% (Fig.19), whereas PON1 activity varied very little between
the PB and LVB plasma samples from the group of patients with EF <40%.

PB Plasma from Control Subjects Showed Much Higher Cholesterol Efflux than
Both Groups of Patients:
Cholesterol efflux study was done using plasma from PB plasma collected
from the control subject group. Following the same method used with the patients’
plasma samples, control plasma samples were incubated with foam cells
containing 3H-cholesterol for 4 hours. The results obtained with the assay showed
that there was a wide variation in the values of cholesterol efflux among the control
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group. However, even with the high standard deviation the control group showed
a significantly higher cholesterol efflux value when compared with the cholesterol
efflux values obtained with the PB plasma from HF patients with lower EF (Fig.
22). The cholesterol efflux capacity observed in the PB plasma from the control
group and the patient group with normal EF (>60%) were not very different.

Discussion
The loss of anti-atherogenic functions of HDL has been studied extensively
in the last few decades. One of the major consequences of the dysfunctionality of
HDL is impairment of HDL induced cholesterol efflux, clearance of free cholesterol
and thus RCT. While aging is thought to be responsible for the reduced antioxidant
activity and RCT capacity of HDL (148), oxidation of HDL and modification of HDL
during acute inflammatory response have received tremendous attention. Among
different subpopulations of HDL, HDL3 is believed to have most of the
cardioprotective functions associated with HDL. HDL3 is most effective in
stimulating cholesterol efflux from macrophages. Independent studies have
showed that age-related reduced efficiency and metal-ion induced oxidation,
hugely impaired the capacity of HDL3 to induce cholesterol efflux (148-150). Loss
of functionality of HDL is also known to be associated with MPO mediated
oxidation of apoA-I. Oxidative modification of apoA-I impairs the interaction
between apoA-I and ABCA1 and the cholesterol efflux is affected.
Dysfunctionality of HDL often refers to the loss of its antioxidative function.
Antioxidant properties of HDL, in the context of protecting LDL from oxidative
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modification, are closely related to the enzymes harbored by or associated with
HDL. PON1 is an HDL associated enzyme and plays an essential role as an
antioxidant enzyme. PON1 is secreted from the liver and its interaction with apoAI provides stability to this enzyme as HDL acts as the hydrophobic harbor. PON1
catalyzes hydrolysis of lipid peroxides, fatty acid peroxides and hydrogen
peroxides to prevent LDL modification (151). HDL associated PON1 prevents the
oxidation of LDL in several ways- by inhibiting the formation of conjugated dienes,
peroxides and by decomposing highly cytotoxic aldehydes. Additionally, PON1
protects HDL itself from oxidative stress (136, 152) and helps HDL to maintain its
function associated with RCT (136). PON1 is also believed to prevent oxidized
phospholipid mediated monocyte chemotaxis and macrophage activation (86),
thiolactone associated endothelial injury and fatty streak formation and improves
the capacity of HDL to induce cholesterol efflux from macrophages (47, 86).
Plasma concentration of PON1 is markedly reduced under several pathological
conditions such as diabetes, hypercholesterolemia and myocardial infarction
(136). Recent study by Deakin et al (152), showed that oxidation of apoA-I
associated with HDL impairs the capacity of HDL to stimulate the secretion of
PON1 from liver and activation of the enzyme. This generates a vicious cycle in
which PON1 fails to protect HDL from oxidative stress and makes it particularly
prone to chlorination (152). As a result, HDL becomes less effective as an
antioxidant and fails to protect LDL from oxidative modification.
All the patients included in this study were undergoing various routine
cardiovascular surgeries and were categorized into 2 groups based on their left92

ventricular EF. Our preliminary results showed that the patients with low leftventricular EF had higher Ox-LDL content in their PB plasma when compared with
the patients with normal EF values (unpublished data). This observation led to the
hypothesis that HDL functionality would vary between these two groups, as
oxidative modification of LDL is attenuated by the antioxidative functions of HDL.
The goal of this study was to evaluate the quality of HDL by performing cholesterol
efflux assay.
Foam cells containing fluorescently labeled or radiolabeled cholesterol were
generated by incubating RAW 264.7 macrophages with cholesterol (unlabeled and
NBD or 3H-Cholesterol)/ Lyso PtdCho mixed micelles for 18 hours in the presence
of 40 µM oleic acid (146). Foam cells were incubated with PB plasma from 2
different groups of patients with low and normal EF for 4 hours and efflux of
cholesterol was measured. When the assay was performed with foam cells
containing NBD-cholesterol, we observed that proteins present in the plasma were
interfering with the measurement of the effluxed NBD-cholesterol. These samples
were subjected to a deproteination procedure in order to precipitate the protein
and then the amount of effluxed NBD-cholesterol was measured. As expected,
cholesterol efflux assay performed with foam cells containing 3H-cholesterol did
not require any additional treatment before the amount of effluxed cholesterol was
measured in the medium. However, the results obtained from both of these assays
were very similar in terms of amount of effluxed cholesterol. The PB plasma from
the patients with normal range of EF induced approximately 1.5-fold more
cholesterol efflux than that from the patients with low range of EF (Fig.18). This
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observation corroborated our previous observation regarding the content of OxLDL present in the PB plasma.
EF is an indicator of normal functioning of the heart as the EF value refers
to the amount blood being pumped out of the blood with each contraction. The
capacity of the heart to pump out the optimum amount of blood can be diminished
for various reasons and current studies show that HF is common even with
preserved systolic function or normal EF (153). Chronic heart disease conditions
are often associated with increased oxidative stress biomarkers such as lipid
peroxides and malondialdehyde in the blood (154, 155). In accordance to these
previous findings we observed that PB plasma from the HF patients with low EF
showed increased sign of oxidative stress than the patients with normal EF. The
presence of high level of Ox-LDL in the PB of patients with low EF could be
explained by the compromised quality of HDL. Reduced cholesterol efflux capacity
of the HDL present in the PB plasma of the group with lower EF indicated the
possibility of and oxidative modification of HDL. Furthermore, to evaluate the
quality of HDL a standard PON1 assay was performed. As expected, the PB from
the group with normal EF showed more than 2-fold increased PON1 activity than
that from patients with low EF (Fig. 19). This observation not only confirmed our
initial evaluation regarding the quality of HDL present in the PB, it also explained
why different amounts of Ox-LDL were present in the blood of these 2 groups. As
PON1 is known to be the major HDL associated enzyme that protects LDL from
oxidative modification, the low PON1 activity observed in the PB plasma of patients
with low EF validated the higher content of Ox-LDL. On the other hand, the PB
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plasma from the patients with normal EF showed higher cholesterol efflux capacity
indicating better HDL functionality, and higher PON1 activity in the corresponding
plasma corroborated the lower content of Ox-LDL.
As we expected, the concentration of HDL observed in the plasma of these
patients did not represent the functionality of HDL. In fact, the average HDL
concentration found in the patients with low EF (36.3 mg/dL) was slightly higher
than that found in the patients with normal EF (36 mg/dL). However, when the
cholesterol efflux capacity and PON1 activity associated with HDL were compared,
it became clear that patients with normal EF have higher amount of functional HDL
than that found in the patients with low EF (Table 1.). From this observation it can
be concluded that the measurement of cholesterol efflux capacity or PON1 activity
is a much better indicator of HDL quality and functionality than the concentration
of HDL alone.
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Table 1. Cholesterol Efflux Capacity and PON1 Activity Associated with HDL
from Patients with Low and Normal EF.

Ejection Fraction
Subject identifier
(%)
Sample 22
25-30
Sample 23
30-35
Sample 26
< 20
Sample 27
< 20
Sample 43
35
Sample 46
23
Sample 52
20-25
Sample 53
17
Sample 56
25
Sample 58
< 20
Sample 70
30-35
Sample 71
23
Sample 35
Sample 37
Sample 42
Sample 50
Sample 44
Sample 55
Sample 61
Sample 65
Sample 67
Sample 94
Sample 111
Sample 114

60-65
68
67
63
61
60-65
60-65
60-65
60-65
60
60-65
60-65

Plasma HDL
concentration
(mg/dL)
34
51
Unknown
47
28
43
25
39
7
Unknown
52
37
22
45
38
69
24
25
Unknown
33
42
47
28
23

Cholesterol efflux
PON1 activity
(nmoles)
(nmoles/ min/ ml)
2.23
24.78
2.37
32.77
2.57
31.65
2.89
26.40
3.37
26.90
2.83
30.96
3.05
27.53
3.17
34.71
2.60
33.15
2.96
29.28
2.76
30.40
2.58
29.03
5.42
4.83
4.66
5.93
5.21
4.91
4.78
5.64
4.87
4.97
4.88
5.34

75.00
65.45
60.58
67.29
58.18
71.82
66.57
91.95
76.15
75.09
60.30
59.43

Surprisingly, the cholesterol efflux assay and the PON1 assay using the leftventricular blood plasma collected from these 2 groups led to equivocal
conclusions. LVB plasma from both groups showed low cholesterol efflux capacity
and low PON1 activity. The cholesterol efflux capacity of PB and LVB plasma
collected from the patient group with low EF were almost in the same range (Fig.
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20a). The same was true for PON1 activity assay (Fig. 21a). However, the LVB
plasma collected from the patients with normal EF gave very different profiles of
cholesterol efflux capacity and PON1 activity when compared with the results
obtained by using the PB plasma collected from the same group of patients. The
cholesterol efflux capacity (Fig. 20b) and the PON1 activity (Fig. 21b) in the LVB
plasma from the patients with normal EF were much lower than those observed in
their PB plasma, which might indicate that there is more oxidative modification of
the HDL in LVB plasma than in PB plasma. This unexpected observation arises
several interesting questions. Use of PB plasma alone to study cholesterol efflux
and associated quality of HDL might not be sufficient to predict the cardiovascular
health of a person. Is there a repair mechanism present in our body that attenuates
or reverses the oxidative stress related modifications of lipoproteins present in the
blood circulating in the peripheral tissue?
It would be interesting to note here that the PB plasma collected from the
control group subjects showed a much higher cholesterol efflux capacity than that
from the groups of patients with low EF (Fig. 22). In accordance to our exclusion
criteria this is not surprising as the control group subjects did not have any history
of chronic heart diseases. However, to determine the quality of HDL and to
evaluate the conditions associated with oxidative stress in the control group
subjects, more studies needed to be performed. The average blood cholesterol
level found in the control group was much higher (58.25 mg/dL) than either of the
HF patient group included in the study and can be considered to be in the range
to have cardioprotective functions. Nonetheless, the cholesterol efflux capacity of
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the PB plasma from the control group and the group with normal EF were very
similar even though the concentration of HDL varied widely (average HDL
concentration in the control group: 58.25 mg/dL and in the HF patient group with
normal EF: 36 mg/dL).
Our initial studies indicated that the PB from the patients with low leftventricular EF showed elevated sign of oxidative stress when compared with that
from the patients with normal EF. Further investigation revealed that patients with
low EF had more amount of dysfunctional HDL in the peripheral and LVB when
compared with the PB collected from patients with normal EF. Functionality of HDL
was evaluated by performing cholesterol efflux assay and by assaying PON1
enzyme activity. All the results taken together, we concluded that patient group
with low EF had markedly reduced amount of functional HDL.
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Figure 18. PB Plasma from the Patients with Lower EF Showed Lower
Cholesterol Efflux Capacity.
a) PB and LVB plasma samples from patients with low and normal EF were incubated with
foam cells loaded with NBD-cholesterol and the efflux of NBD-cholesterol was measured
following deproteination of the samples; b) PB and LVB plasma samples from the 2 groups
of patients were incubated with 3H-cholesterol containing foam cells and the efflux of 3Hcholesterol was measured, CPM values were converted to nmoles of effluxed cholesterol.
Cholesterol efflux associated with PB plasma from patients with normal EF was compared
with that from patients with low EF. Similarly, cholesterol efflux associated with the LVB
plasma from the 2 groups were analyzed. All the samples were analyzed in triplicates and
values are expressed as mean ± SD (n ≥ 3). *** < 0.005 (one-way ANOVA with
Bonferroni’s multiple comparison test).
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Figure 19. PB Plasma from the Patients with Normal EF Showed Higher PON1
Activity.
PB and LVB plasma samples from patients with low and normal EF were analyzed for HDL
associated PON1 enzyme activity and the conversion of p-NPA to Nitrophenol was measured by
reading absorbance at 410 nm. PON1 activity associated with PB plasma from patients with normal
EF was compared with that from patients with low EF. The comparison of PON1 activity related to
LVB plasma between the 2 groups was done similarly. All the samples were analyzed in triplicates
and values are expressed as mean ± SD (n ≥ 3). *** < 0.005 (one-way ANOVA with Bonferroni’s
multiple comparison test).

100

Figure 20. Peripheral and LV Blood Plasma from the Same Patient with Low
EF and/ or Normal EF were Compared in Terms of Capacity of Cholesterol
Efflux.
a) 3H-cholesterol efflux associated with peripheral and LVB plasma from the patient group with low
EF were measured and cholesterol efflux capacity of the PB plasma and the LVB plasma taken
from the same patient was compared; b) Similarly, cholesterol efflux induced by the PB plasma and
the LVB plasma from the patients in the normal EF group were compared. All the samples were
analyzed in triplicates and values are expressed as mean ± SD (n ≥ 3).
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Figure 21. PON1 Activity Associated with the PB Plasma and the LV Blood
Plasma were Compared for each Patient Belonging to either Low or Normal
EF Group.
a) PON1 activity related to the PB plasma and the LVB plasma was compared for each patient in
the low EF group; b) Similarly it was done for the patients belonging to the normal EF group. All the
samples were analyzed in triplicates and values are expressed as mean ± SD (n ≥ 3).
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Figure 22. Cholesterol Efflux Capacity Associated with Control Group with
No History of Chronic Heart Disease and Patients Groups with Low and
Normal EF were Compared.
PB plasma from the control group and the peripheral and LV blood plasma samples from the 2
groups of patients were incubated with 3H-cholesterol containing foam cells and the efflux of 3Hcholesterol was measured. Cholesterol efflux associated with the PB plasma from the control group
was compared with peripheral and LVB plasma from patients with low and normal EF respectively.
All the samples were analyzed in triplicates and values are expressed as mean ± SD (n ≥ 3). *** <
0.005 (one-way ANOVA with Bonferroni’s multiple comparison test).
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CHAPTER 4: CONCLUSION AND DISCUSSIONS
Lipoproteins which are intricately associated with atherosclerosis play
crucial roles in the formation or regression of atherosclerotic plaque. While high
levels of plasma LDL are directly related to the risk of increased plaque burden,
the relationship between HDL and the regression of the plaque burden is more
complex. Increased concentration of plasma LDL leads to the initiation of a series
of events which are pro-inflammatory in nature. Secretion of pro-inflammatory
factors and cytokines stimulate differentiation of the monocytes to the adherent
macrophages and expression of SRs. Modified LDLs, such as Ac-LDL or Ox-LDL
act as ligands for these SRs and the uptake of modified LDLs by SRs or other
mechanisms starts the events leading to atherosclerotic plaque formation.
Macrophages loaded with unesterified and esterified cholesterol, known as foam
cells, are the key components of these plaques. To study various aspects of
atherosclerotic plaque development and RCT, foam cells are regularly generated
in vitro. In vitro generation of foam cells traditionally involves incubation of
macrophages with Ac-LDL or Ox-LDL probed with radiolabeled cholesterol.
However, as described in the chapter 2, there are several drawbacks associated
with the use of isolated and modified LDL, used for this purpose. One of the most
important restraints of this technique is its limited use in the clinical set up. As
described before, LDL is hard to isolate and even harder to store for long time
without causing unwanted modifications to the lipoprotein. Thus, developing an
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assay technique which can used in the doctors’ office or diagnostic clinic is really
hard when LDL is used to generate foam cells.
RCT is a unique defense mechanism of our body that prevents or restricts
atherosclerotic plaque formation. HDL is the key player involved in RCT. HDL with
or without the help of transporters and receptors induce efflux of cholesterol from
macrophage foam cells and delivers the cholesterol to the liver for excretion.
Studies from several independent laboratories in the last decades of the 20th
century strongly established the inverse relationship between HDL and
cardiovascular diseases. Initially it had been thought that the quantity of plasma
HDL is the most important indicator to diagnose CAD and the higher is the
concentration of plasma HDL, less are the chances of atherosclerotic plaque
development. However, the last few years of research indicated that the
relationship between HDL and atherosclerosis is much more complex.
HDL can be considered as the ‘guardian angel’ which often multi-tasks to
protect the cardiovascular health of our body. Apart from inducing cholesterol efflux
and preventing plaque formation, HDL prevents oxidation of LDL and exerts antiinflammatory, anti-apoptotic and anti-thrombotic effects. In other words, if LDL is
called pro-atherogenic, HDL can definitely be referred as anti-atherogenic in
function. Nonetheless, the anti-atherogenic properties of HDL are closely
associated with the quality of this lipoprotein and not its quantity in the serum.
Oxidation of HDL renders it dysfunctional and often pro-atherogenic. Ox-HDL fails
to prevent LDL oxidation and is less effective in inducing cholesterol efflux from
the foam cells. Oxidation of HDL is associated with the oxidation of its major
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apolipoprotein, apoA-I, the oxidation of its anti-oxidant enzyme PON1 and often
the displacement of apoA-I or PON1 with SAA. While the quantification of PON1
or SAA gives an indirect evaluation of the quality of HDL, measuring the efficacy
of cholesterol efflux in the presence of HDL is the most direct approach to
determine HDL quality.
For the last several years, different approaches have been taken to quantify
cholesterol efflux or RCT and assess the quality of HDL from subjects with or
without the history of CAD. No matter what the approach is, these studies start
with the generation of in vitro foam cells. In this study, we intended to develop an
assay which can quickly and effectively measure cholesterol efflux from foam cells
using patients’ plasma samples. Furthermore, our goal was to develop an assay
which can be used in the doctors’ office or in the diagnostic labs very efficiently
without compromising the quality of the results.
The longest and very tedious step in foam cell generation is the isolation of
LDL. Our goal was to enrich macrophages with free or esterified cholesterol in a
faster and more efficient way. To overcome the biggest obstacle of solubilizing the
highly hydrophobic cholesterol in aqueous solution, we have used Lyso PtdCho.
Lyso PtdCho is an amphiphilic biological detergent which has been used by our
laboratory before to enrich cells with highly non-polar β-carotene. We manipulated
this technique further to deliver cholesterol or CE to the macrophages. We
established that the foam cells generated by this technique were physiologically
relevant by doing lipid droplet staining and quantifying the accumulation of
cholesterol in the total lipid fraction and CE fraction. These foam cells were also
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enriched with fluorescently labeled or radiolabeled cholesterol. We further
established that micelle mediated foam cells generation is a highly reproducible
technique.
One of the crucial drawbacks for Ac-LDL or Ox-LDL generated foam cells
is the instability of the reagent. Ac-LDL or Ox-LDL are highly unstable and need to
be used within 4-5 days since isolation. We showed that the micelles containing
cholesterol (unlabeled and labeled) and Lyso PtdCho were highly stable at 4°C
and -20°C for more than 4 weeks. It was further established that foam cells
generated with stored micelles are qualitatively and quantitatively similar to the
ones generated with freshly prepared micelles.
The generation of foam cells with mixed micelles was not a cytotoxic
technique. Lyso PtdCho, which is a cytolytic detergent, was metabolized into noncytotoxic PtdCho during micelle uptake by the macrophages. Unlike Ac-LDL or OxLDL mediated foam cell generation, micelle mediated foam cell development was
completely independent of SR associated uptake. It is important to mention that
generation of foam cells with mixed micelles is a very rapid technique and the cells
were enriched with unlabeled and labeled cholesterol within 4-6 hours of
incubation with the micelles. For the diagnostic screening purpose it would be
crucial as the whole assay can be completed within 12 hours starting from the
preparation of mixed micelles. We utilized the micelle generated foam cells to
evaluate the cholesterol efflux induced by native and Ox-HDL. As expected,
cholesterol efflux induced by native HDL was much higher in quantity when
compared with the same concentrations of Ox-LDL associated cholesterol efflux.
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Based on this observation, we hypothesized that these foam cells could be
further utilized to screen patient samples to identify subjects with high or low level
of Ox-HDL. Samples from human subjects with no history of CAD were used as
the control group. The 2 other groups of patient samples belonged to human
subjects undergoing routine cardiovascular surgeries [coronary artery bypass
grafting (CABG), valve repair/replacement (AVR, MVR, TVR: aortic, mitral, or
tricuspid valve replacements) or other open heart surgeries]. Among these, one
group of patients had normal range (55-70%) of left-ventricular EF, while the other
group had clinically defined low range (<40%) of left-ventricular EF.
Our preliminary studies revealed that the patient group with low EF showed
higher level of Ox-LDL in the blood plasma when compared with that with normal
EF. As HDL protects LDL from oxidation and oxidized status of LDL is closely
associated with the quality of HDL, we decided to evaluate the quality of HDL by
performing cholesterol efflux assay using micelle mediated foam cells. The
cholesterol efflux study clearly showed that the amount of cholesterol effluxed from
the foam cells in presence of plasma from patients with normal EF was much
higher than in the presence of plasma samples from the group with low EF. On
average the efflux of cholesterol upon incubation of foam cells with PB plasma
from patients with normal EF was ~1.6 fold higher. However, the amount of
effluxed cholesterol from the foam cells after incubating with PB plasma from the
control group showed a significantly higher value than the rest of the groups. We
concluded that the patients with low EF had a higher level of dysfunctional or OxHDL in their PB as the plasma failed to induce efficient cholesterol efflux when
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compared with the control group or the patient group with normal EF. We further
concluded that patients with normal range of EF have lower level of Ox-HDL in
their PB.
To evaluate the quality of HDL we further performed PON1 assay. PON1
assay is another indirect method to investigate the quality and the functionality of
HDL beside the measurement of Ox-LDL. The results from PON1 assay clearly
reflected our previous observation. Patients with low EF showed lower PON1
activity in the PB plasma when compared with the patients with normal EF. As
inactivation of PON1 can be a direct consequence of oxidation, which indicates
oxidation of HDL, estimation of PON1 activity further elucidates the quality of HDL.
However, left-ventricular blood plasma from both groups of patients showed low
level of cholesterol efflux, low PON1 activity and high level of Ox-LDL. This finding
was surprising for the group with normal EF range as the left-ventricular blood
plasma appeared to have more Ox-HDL than their PB plasma.
This project was designed to develop a quick and efficient assay to measure
and evaluate the quality and functionality of HDL. Our goal was to develop a
screening assay which can be utilized by the doctors’ office or by diagnostic clinics
to screen a large number of patient samples to evaluate the efficiency of their RCT.
We successfully generated physiologically relevant in vitro foam cells and utilized
them to screen patient samples to evaluate the quality of HDL. This novel
technique is highly reproducible and reliable.
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This novel technique of delivering macromolecules to the cells can be
further manipulated to deliver other hydrophobic large molecular cargos to the
cells.
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